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ABSTRACT

T lymphopoiesis has been an intense focus of immunological research since the
discovery of the major histocompatibility complex (MHC) and T cell mediated transplant
rejection. Additionally, researchers have long appreciated the role ofT cells, and their
development, in autoimmune disorders. Interest in this field has increased upon the
realization that many leukemic oncoproteins are the very factors that control normal T
cell development. Thus, the transcriptional networks that drive the function and
development of T lymphocytes are closely linked with disease states.
Growth Factor Independence 1 (GFII) and GFIlB are two very similar
transcriptional repressor oncoproteins that are encoded by two different genes. Though
nearly identical in their DNA binding and repressor domains, GFIl and GFIlB are
differentially expressed in normal tissues and in tumors of lymphoid lineage. GFIl is
frequently activated in mouse T cell leukemias, whereas GFIlB has not been found in T
cell tumors. The work described in this dissertation provides insight into this
phenomenon by delineating functional differences for GFIl and GFIlB in T cells.
The first set of experiments compares the phenotypes engendered by transgenic
expression of either GFIl or GFIlB in developing and mature T lymphocytes. These
analyses revealed that GFIl enhances the response to T cell activation, whereas GFIlB
decreases this response. Furthennore, transgenic GFIl B causes defects in thymocyte
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development, some of which result from a lack of survival signals. These defects can be
corrected by transgenic expression of either BCL2, an inhibitor of apoptosis, or GFIl,
suggesting that GFIl and GFIlB play opposing roles in T cell survival.
At least part of1he effect of transgenic GFIlB results from GFIlB-mediated
repression of Gfil transcription. We show that the transcription of Gfil is repressed in T
cells by both GFIl and GFIlB and that this is the result of direct binding to evolutionarily
conserved GFIl/GFIlB recognition sequences in the Gfil promoter. Furthermore, we
provide evidence that endogenous GFIl regulates its own promoter in T cells, but not in a
myeloid lineage cell line.
Finally, a more detailed analysis of the effect ofGFIlB in T lymphopoiesis
confirms a role for GFHB in the survival and differentiation ofthymocytes. This
analysis revealed that transgenic expression ofGFIlB results in altered expression of
several members of T cell receptor (TCR) signaling pathways that are largely responsible
for the survival and differentiation ofthymocytes. The activity of the downstream
effectors of these pathways appears to be decreased, providing mechanistic insight in to
the function of GFIlB in T cells.
Our work is the first to describe a role for GFIB in T cells. We demonstrate that
GFIlB negatively regulates the cellular response to activation through the TCR complex
and provide preliminary evidence of a mechanism by which GFIIB mediates these
effects. Furthermore, wle delineate functional differences for GFIl and GFIlB in T cells,
providing insight into the differential expression of these two transcription factors.
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CHAPTER I
INTRODUCTION, BACKGROUND, AND RESEARCH OBJECTIVES

Hematopoiesis, the immune system, and T cell develo.,ment.

Hematopoiesis-the process by which new blood cells are generated from selfrenewing pluripotent stem cells residing in the bone marrow--consists of two major
arms, myelopoiesis and lymphopoiesis. Cells that are generated in the myelopoietic
process include erythrocytes, which carry oxygen and carbon dioxide through the blood
stream, and megakaryocytes, which generate platelets, cells that are necessary for blood
clotting at the sites of injury. The remaining myeloid cells, along with all the cells of
lymphoid lineage, make up the immune system. Immune cells protect the body from
invasion and disease.
There are two basic classes of immune response-innate immunity and adaptive
immunity-and each component of the immune system contributes to one or the other.
Innate immunity is the body's first response, occurring within hours of invasion. This
response is not pathogen-specific, and is carried out by several types of cells as well as
complement factors. Epithelial cells function in innate immunity by forming physical
barriers against pathogens. Phagocytes (a class of myeloid cells consisting of
macrophages and neutrophils) act in the innate immune response by engulfing and
destroying invading pathogens. The lymphoid cells that participate in innate immunity
are natural killer (NK) cells. NK cells are programmed to destroy any non-self cell with
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which they come into contact. NK cells discriminate between self and non-self cells by
recognition of self-MHC Class I on the surface of other cells. (Major Histocompatibility
Complex, MHC, is discussed in more detail below.) This recognition signals the NK cell
to suppress the killing machinery, thereby preventing the destruction of self cells.
The second line of defense, adaptive immunity, occurs over a period of days, and
is pathogen-specific. In this process, the immune system recognizes and adapts to the
presence of invading pathogens, resulting in the specific elimination of either invading
organisms or of infected host cells. Furthermore, the adaptive immune system has
memory. That is, after the initial infection by an invading organism has been cleared by
the adaptive immune system, re-introduction of the same pathogen results in a more rapid
and efficient response. Adaptive immunity comes in two forms, humoral immunity and
cell-mediated immunity, which are executed by Band T lymphocytes, respectively. B
cells mediate humoral immunity by secreting antibodies that recognize and bind to
pathogens, resulting in the destruction of the invader by phagocytes.
Cell-mediated immunity is controlled by T cells, which become activated against
pathogens by interaction of the membrane-bound T cell receptor (TCR) complex and
pathogenic antigens presented on the surface of other host cells in the context of self
major histocompatibility complex (MHC) molecules. MHC molecules are present on the
surface of all cells within the body and, under normal physiological conditions, present
self-antigens to TCRs on mature T cells. This constant low-level interaction contributes
to the maintenance and survival of a diverse T cell population, a process known as T cell
homeostasis. However, upon cellular infection or phagocytosis of an invading organism,
pathogen-specific proteins are processed to produce peptide antigens, which are bound by
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MHC and presented on the cell's surface. It is this antigenIMHC complex that is
recognized by the pathogen-specific TCR on circulating T cells, initiating and sustaining
a cellular immune response. (See Figure 1.)
There are two types of T lymphocytes, helper T cells and cytotoxic T cells. T
helper cells are activated by antigen in the context of MHC Class II, which is expressed
almost exclusively by professional antigen presenting cells. Once activated, a T helper
cell proliferates (a process known as clonal expansion), promotes the proliferation ofB
cells, activates macrophages, and promotes inflammation, all of which can contribute to
the destruction of the invader. Cytolytic T cells are activated by antigen in the context of
MHC Class I molecules on the surface of infected cells, resulting in the specific lysis of
the infected target cell by the T cell. All cells express MHC Class I, because any cell in
the body is a potential target for infection.
All T cells can be experimentally identified by surface expression of the T cell
receptor (TCR) complex. Furthermore, T helper cells are easily identified by the surface
expression of the CD4 co-receptor molecule, and cytotoxic T cells are characterized by
the expression of the CD8 co-receptor. The TCR complex is responsible for antigen
recognition and initiation of intracellular activation signals, the latter being largely
regulated through a family of surface proteins known as the CD3 complex. Both CD4
and CD8 co-receptors assist in the initiation of signaling cascades, and no qualitative
difference between the signaling events mediated by the two co-receptors has been
defined, leaving a mystery as to the mechanisms governing, and the reasons for, the
specificity of expression of these two co-receptors on the two classes of T cells.

-3-

Figure 1. T Cell Receptor (TCR)-Major Histocompatibility Complex (MHC)
interaction. Schematic representation of a TCR recognizing and binding to peptide
presented by MHC.

C~

and V~, respectively, are the constant and variable regions of the

TCR ~ chain. The peptide antigen is bound in the groove between the a and
the MHC molecule, and is shown as a rectangle.
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Antigen specificity and affinity of the TCR complex are dictated by the sequences
of the TCR a and

p chains.

Diverse sequences are generated by chromosomal

rearrangement of the variable regions of these genes, which is mediated by the products
of Recombinase Activating Genes (RAG) 1 and 2, and cannot occur in the absence of
either RAG 1 or RAG2. Furthermore, surface expression of one successfully rearranged
TCR a or p chain results in signaling that suppresses further rearrangement on the other
allele, a process known as allelic exclusion. Allelic exclusion results in the expression of
only one TCR on most T cells, ensuring that each cell has specific affinity for antigen and
MHC, providing the required diversity of the cellular immune system. In addition to
controlling the function of mature T cells in immune responses, the affinity/avidity of
TCRlMHC interactions also determine the fate of developing T cells in the thymus, a
process known as T lymphopoiesis (recently reviewed in (1 ;2)).
T lymphopoiesis begins when T cell precursors, prior to committing to the T
lineage, leave the bone marrow and enter the thymus. The development of thymocytes is
tracked and partially defined by the cell-surface expression of the CD4 and CD8 coreceptors (see Figure 2). The earliest thymocytes express neither CD4 nor CD8 and are
referred to as double negative (DN) cells. After commitment to the T lineage, DN
thymocytes express a pre-TCR, which is a heterodimer consisting of the pre-Ta and a
rearranged TCRP chain. Signals from the pre-TCR are required for further development
and differentiation into the next stage ofT lymphopoiesis, the double positive (DP) stage,
where both CD4 and CD8 are expressed on the cell surface. Rearrangement of the TCRa
chain occurs upon differentiation into the DP stage. Once expressed, the TCRa chain
replaces pre-Ta and provides the final requirement for a mature TCR complex, signals
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Figure 2. The stages of T lymphopoiesis. A. Schematic representation of the T
lymphopoietic process. The most primitive thymocytes express neither CD4 nor CD8
(double negative, DN). This stage can be further sub-classified based on the expression
of surface markers CD44 and CD25. Survival and differentiation during the DN stages
are dependent upon signals from cytokines, such as IL-7, and from the pre-TCR. In the
next stage of differentiation, cells express both CD4 and CD8 simultaneously (double
positive, DP), and the TCR replaces the pre-TCR. These early stages ofT lymphopoiesis
occur in the cortex of the thymus. Finally, thymocytes down-regulate either CD4 or CD8
to become CD4+ or CD8+ single positive (SP), translocate into the medulla and undergo
final maturation. This lineage commitment depends on signals from the TCR. B. Flow
cytometric analysis of CD4 and CD8 expression on C571B16 mouse thymocytes. The
subpopulations are gated and identified.
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from which are necessary for further development. The final stage of thymocyte
maturation requires down-regulation of one or the other co-receptors and results in
differentiation into either CD4 (helper) or CD8 (cytolytic) single positive (SP) T cells.
This stage of maturation requires the integration of two distinct processes-positive
selection, a process by which a cell receives survival signals; and lineage commitment, a
process by which a cell makes fate decisions that result in the expression of a single coreceptor. Neither process has been fully defined, though extensive research is ongoing in
both areas. However, positive selection is absolutely dependent upon appropriate TCRmediated signals. In the thymus, as in peripheral T cell homeostasis, TCR signaling
events are initiated by interaction of the TCR with self-peptide presented by MHC on the
surface of thymic antigen presenting cells. It is the affinity of this interaction that
determines whether the maturing T cell survives or dies.
Signals from both cytokine receptors and the TCR are required for survival and
positive selection. Death of developing thymocytes occurs as a result of either very weak
or very strong TCR signals. An insufficient signal results in apoptotic death that is
referred to as "death by neglect", while a very strong signal results in apoptotic death that
is known as negative selection. Death by neglect assures that incompetent T cells are not
released into the immune system, while negative selection assures that autoreactive T
cells do not escape into the periphery and is vital to the prevention of autoimmune
disease.
Survival of developing T cells is dependent upon an intermediate strength of
signal from the TCR. A thymocyte, in the course of development and migration through
the thymus, has contact with many different antigen presenting cells (APCs), each
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presenting self-peptidelMHC complexes for interaction with the TCR. Furthermore,
cytokines, expressed at different anatomical locations within the thymus, interact with
their corresponding receptors on the surface of developing thymocytes to provide
survival signals. For example, deletion ofIL7Ra results in drastically reduced thymic
cellularity resulting from a severe block to development at the DN stage (3). Thus, a
combination of TCR signaling and cytokine signaling is critical for T lymphopoiesis.
Lineage commitment is closely linked to the MHC-specificity of the TCR;
typically, CD4 SP T cells are restricted on MHC Class II molecules, while CD8 SP T
cells are restricted on MHC Class I molecules. Furthermore, the MCH loci are comprised
of several different genes that are highly polymorphic, and it is these polymorphisms that
form the basis of self and non-self specificity of recognition by T cells. In humans and
outbred animals, the two different alleles ofMHC genes, both of which are expressed,
encode distinct polymorphic proteins, resulting in even greater diversity. Each allele is
designated as a specific haplotype, since it comprises only half of the genetic and
proteomic information. On the other hand, in inbred laboratory mouse strains, both
alleles of the MHC locus encode the same polymorphisms, resulting in the expression of
only one protein for each MHC gene. Therefore, every gene in the MHC locus of these
mice has the same haplotype designation, which is a small letter of the alphabet (some
common haplotypes are b, d, and k). Many T cells from a mouse with a particular
haplotype, by virtue of TCR-MHC interaction, recognize as foreign MHC molecules of
any other haplotype. This recognition forms the basis for transplant rejection and,
indeed, was the early discovery that led to the intense interest that has developed in the
area of T lymphopoiesis.

- 10-

While much is understood about phenotypic and cell-surface changes that
accompany T lymphopoiesis, and quite a bit has been discovered about early signaling
events in TCR-mediated activation, a minimal understanding exists of the transcriptional
network that links the early signaling events to the phenotypic changes. Several
transcription factors have been implicated in the differentiation of thymocytes, including
EGR-I, Notchl (a cell-surface receptor that is cleaved upon ligand binding to form
intracellular Notch (lCN), a transcriptional regulator), and the E2A gene products, El2
and E47 (4-6). Additionally, the activity of certain transcription factors has been shown
to increase upon TCR activation, including that ofNFAT, NFKB, and AP-l, each under
the control of distinct second messengers and/or signaling pathways (recently reviewed in
(7)). Furthermore, different arms of the mitogen activated protein kinase (MAPK)
pathway have been shown to preferentially activate during either positive or negative
selection, providing some insight into how the activation of the same TCR can lead to
dichotomous outcomes (recently reviewed in (1)). However, an understanding of the
integration of activation, survival and differentiation signals, which is the key to
understanding the continuous process of T lymphopoiesis, has remained elusive.

Gftl and GftlB.
The Growth Factor Independence-l (GFIl) and GFIlB proteins are closely
related nuclear oncoproteins that may regulate cytokine pathways. Gfil was originally
identified as the gene upregulated by insertion of Moloney murine leukemia virus
(MoMLV) in a thymic lymphoma that was selected for its ability to grow in the absence
of the T-cell cytokine IL-2 (8). GFIl is mildly anti-apoptotic and inhibits growth arrest

- 11 -

ofIL-2 dependent T cell lines under conditions of limiting IL-2 (8;9). Furthermore,
forced expression of Gftl potentiates the outgrowth of cell lines that do not depend on the
addition ofIL-2 to the media, without inducing production ofIL-2 within the culture (8).
In fact, 2780a cells that were infected with Gftl-encoding retrovirus escaped both

apoptosis and Gl arrest induced by the withdrawal ofIL-2 (9). GftlB was identified by
low stringency hybridization screening with a eDNA probe encoding the zinc-finger
region of Gftl (10). GFIlB inhibits both growth arrest and IL-6-induced differentiation
ofMl myelomonocytic cells (10).
GFIl and GFIlB are 97% homologous in the carboxy-terminal 165 amino acids
that encode six Cys-His zinc fingers. An amino-terminal20-amino-acid SNAG domain
(found in the Snail and GFIl family of proteins), which is responsible for nuclear
localization and transcriptional repressor function, is also highly conserved (9; 10) (see
Figure 3). In fact, a single mutation in the SNAG domain of the Proline at position 2 to
Alanine (P2A) is sufficient to abrogate repression activity in transient transcription
assays, without affecting either nuclear localization or DNA binding capability (9).
Additionally, 2780a cells infected with P2A-GFIl-encoding retrovirus were unable to
escape Gl arrest in the absence ofIL-2, suggesting that the oncogenic function ofGFIl is
dependent upon its transcriptional repressor activity (9).
Consensus DNA recognition sequences for GFIl and GFIlB have been defined
using bacterially synthesized proteins encoding GST fused to GFIl or GFIlB. Under the
conditions used to define these sites, GFIl and GFIlB bind to virtually identical DNA
consensus sequences, defined as 5'-TAAATCAC(A/T)GCA-3' for GFIl and
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Figure 3. GFIl and GFIlB are similar transcriptional repressors. Gfil and Gfil B
are 97% homologous in the region encoding the Zn fingers and the proteins recognize the
same core DNA sequence. The 20-amino-acid SNAG domain ofGFIlB differs from that
ofGFIl by a single amino acid. Target genes proposed in the literature are listed (10-14)
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5'-TAAATCACTGC(Aff)-3' for GFIlB (10;15). The AATC core was observed in
100% of the sequences that were bound by either GFIl or GFIlB zinc fingers.
Several GFIl targets genes have been suggested by virtue of being up-regulated in
Gjirl - mice. These include 1NFR-associated factor (TRAP) 5, Lung Kruppel Like

Factor (LKLF), and Idl and Id2, all of which have been shown to play roles in T
lymphopoiesis (11). Additional potential targets for GFIl repression include CIEBPa
and PU.l, both of which are required for proper development ofneutrophils (16). Other
putative targets have been identified by chromatin immunoprecipitation (ChIP) analysis,
and include E2F family members E2F5 and E2F6, and Ets family members Ets2 and
cMyc. Furthermore, this analysis identified binding by GFIl to the Gjil B promoter in
three different cell lines (13). Suggested targets for GFIlB have also been identified and
include suppressor of cytokine signaling (SOCS) 1 and 3 (14) and p21 (10).
Despite the extensive similarities ofGFIl and GFIlB, each contains a region
unique in amino acid sequence between the SNAG domain and the Zn fingers, the
activities of which are yet to be defined. These unique regions may be the key to the
distinct physiological roles of these two very similar transcription factors.
Gene deletion studies have shown that Gjil and Gjil B play distinct, pivotal roles
in hematopoiesis. Gjil-deficient mice display both thymic and peripheral T
lymphopenia, with severe abnormalities mpre-T cell development (11; 16; 17).
Furthermore, they display a profound defect in neutrophil differentiation, which leads to
neutropenia (16;17). In support of this apparent role in neutrophil differentiation, several
putative targets ofGFIl have been identified, including ELA2, Azu, AAT, and ACT, all of
which are granulocyte specific genes (13). Additionally, humans have been identified
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that harbor a single allelic mutation of Gjil, presumably resulting in the expression of a
dominant negative protein along with the wild type GFIl (Gjildnlwt). These mutations
were identified in patients with specific types of neutropenia, a phenotype which mimics
that seen in Gjirl - mice. However, unlike Gjil-deficient mice, which have severe T
lymphoid abnormalities, the Gjildnlwt patients display only mild disruptions in T cell
populations.
While Gjil is essential to proper development of lymphoid and granulocytic cells,
gene deletion studies in mice revealed that Gjil B is necessary for the development of
megakaryocytes and for definitive erythropoiesis (18). Deficiency of Gjil B is embryonic
lethal by day E15 (18). In accordance with the hematopoietic phenotypes of Gjil and
Gjil B deficiency, the thymus of adult rats expresses predominantly Gjil, with Gjil B
being undetectable in Northern analysis of whole thymus. Gjil B is the predominant
factor expressed in spleen, the major site of erythropoiesis in adults. Both factors are
expressed in bone marrow, where many types of hematopoietic cells reside, including
hematopoietic stem cells (10).

Specific background and research objectives.
It has been reported that in T cells, transgenic expression of GFIl causes an

increase in the response to TCR-stimulated activation (19-21). In addition, Gjil
transcription is upregulated upon TCR-mediated activation of mature T cells (8;21).
Despite the fact that T lymphopoiesis is driven largely by TCR signals, and that other
genes that are downstream of TCR-mediated activation, such as EGR-l, have been shown
to be instrumental in the development ofT cells (4), the expression pattern and role of
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GFIl in developing thymocytes have not ~en examined. Furthermore, the degree of
sequence homology between GFIl and GFIlB, along with the similar biochemical and
oncogenic functions of these two factors, suggest the possibility that GFIlB, if expressed
in T cells, may perform functions similar to those of GFIl ~
To further examine the function ofGFIl in T cells and developing thymocytes,
and to begin to determine whether GFIlB functions in a similar manner, transgenic mice
were created that express either GFIl or GFIlB in developing thymocytes and in mature
T cells. Examination of these GFIl- and GFIlB-transgenic mice in this laboratory
confirmed that, as previously published, forced expression of GFIl potentiates T cell
activation in vitro. However, GFIlB-transgenic cells responded poorly to TCR
activation, a result directly opposite to that observed in GFIl-transgenic cells.
Furthermore, though expression of transgenic GIF 1 produces no gross thymic phenotype,
expression of transgenic GFIlB results in anomalies in T cell development. Specifically,
GFIlB-transgenic mice produce large numbers of CD4 SP thymocytes with phenotypic
features of maturity, and very few CD8 SP thymocytes.
My goals for this project were three-fold. First, I sought to determine the
physiological relevance of the observed effects ofGFIIB on TCR activation in T
lymphopoiesis by examining expression of endogenous GFIlB in developing
thymocytes. Though Gfil B could not be detected by Northern analysis of whole rat
thymus, the possibility remained that this· factor is expressed in certain subsets of
thymocytes. For example, the DN cells, of which there are four distinct subpopulations,
make up only about 1-3% of total thymocytes. Therefore, ifGFIlB were expressed in
only a subset of DN thymocytes, it would be virtually impossible to detect it by
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previously utilized methods. However, developmental-specific expression of a factor that
negatively regulates TCR signaling could be instrumental in controlling the survival and
differentiation of cells. Secondly, I sought to determine the specific T lymphopoietic
process(es) that may be affected in GFIlB-transgenic mice. Because selection of
thymocytes is central to their development, I focused on determining whether GFIIBtransgenic thymocytes are defective in positive selection, negative selection, or both.
Finally, I wanted to identify downstream targets of GFIl and GFIlB that may mediate
the observed effects on activation. Several downstream effectors of TCR stimulation are
well defined, and the interruption or propagation of any of these pathways could result in
the observed effects on activation. I therefore sought to determine whether GFIlB
transgenic thymocytes display altered expression levels of members of these signaling
pathways.
My second project arose as a result of an observation made regarding the GFIland GFIlB-transgenic mice. Upon Northern analysis of RNA from transgenic
thymocytes, it was observed that in both GFIl- and GFIlB-transgenic animals there was
a reduction in endogenous Gfil message. This presented the possibility that GFIl and
GFIl B may negatively regulate the expression of Gfil. My goals in this project were to
determine whether the observed repression is direct and whether it is conserved among
species and cell types.
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CHAPTER II
INTRANUCLEAR STAINING OF PROTEINS IN HETEROGENEOUS CELL
POPULATIONS AND VERIFICATION OF NUCLEAR LOCALIZATION BY
FLOW CYTOMETRIC ANALYSIS

Introduction.
Traditionally, cells and tissues have been tested for the presence of specific
proteins by biochemical methods such as Western blotting. While this method has
advantages, such as the determination of apparent molecular weight and oligomerization
status, it is rather time-consuming. Furthermore, if a protein is expressed at very low
levels, or in only a fraction of cells in a heterogeneous cell population, Western blotting
can be unreliable, providing false negative results. For example, Western blot analysis
failed to detect the transcription factor Growth Factor Independence-IB (GFIlB) in wild
type thymocytes, even though its expression can be confirmed by RT -peR. It is often
possible to detect nuclear transcription factors by immunofluorescence microscopy,
advantages of which include visual interpretation of data in intact cells, allowing the
determination of not only nuclear vs. cytoplasmic localization, but of subnuclear
localization patterns as well. However, it is difficult to detect poorly expressed proteins
with low affinity antibodies by this method, due in part to limitations of the human eye.
While it is possible to enhance the signal using sophisticated software packages, this
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requires a skilled and knowledgeable microscopist. We therefore turned to flow
cytometry to detect GFIlB in thymocyte subsets.
Flow cytometry is a method whereby the expression of specific molecules can be
assessed on the single-cell level by using antibodies against the proteins of interest. The
protein-specific antibodies are conjugated to fluorochromes, and as the cells pass through
the cytometer, they are exposed to different wavelengths of light to excite the
fluorochromes, which subsequently emit light of a specific wavelength that is detected by
the instrument. Currently, the industry standard flow cytometers allow the simultaneous
detection and separation of four fluorochromes, making it possible to examine the
expression of up to four different proteins on a cell. Traditionally, flow cytometry has
been used to examine cell-surface proteins; however, methods have been developed to
allow the use of this method for examination of intracellular proteins. This often
involves first staining the cells with antibodies against cell-surface molecules in order to
be able to electronically isolate subsets of cell populations. Nonetheless, as in
microscopy, it is difficult to detect poorly expressed intracellular/intranuclear proteins
(such as GFIlB) using this method because of the background produced upon fixation of
cells after surface staining. We tested several methods of fixing and permeabilizing cells
(22;23) with limited success before finding and adapting the method described here.
These procedures are readily amenable to the detection of other nuclear transcription
factors.
We have adapted flow cytometric methods, which can be easily performed by lab
personnel with minimum working knowledge of benchtop flow cytometry instruments, to
detect nuclear proteins using polyclonal antibodies. We have used standard techniques
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for staining the surface of cells, and have modified techniques for fixing the surface stain
and permeabilizing both the cellular and nuclear membranes. Additionally, we have
adapted a method for isolating nuclei (24) in order to determine whether a stain is
nuclear or cytoplasmic. Together, these techniques provide a fast, easy alternative to
classical methods for the detection of intracellular proteins and the determination of
subcellular localization.

Materials and methods.
Mice and preparation of cell suspensions. Mice were housed in the Baxter Barrier

facility at the University of Louisville Medical School. All animal protocols were
approved by the University of Louisville Institutional Animal Care and Use Committee
(IACUC).
Thymi of 4-8-week-old mice were removed into Hank's Balanced Saline Solution
plus 2% heat inactivated fetal bovine serum (HBSS~FBS) and disrupted between the
ends of glass slides. The cell suspension was passed through Nytex mesh to remove
debris, and sedimented in a Sorva1l7 centrifuge at 1200 rpm. The cell pellet was washed
by resuspension in 10 mL of HBSS~FBS and sedimented as described. Cells were
resuspended in 10 mL ofHBSS~FBS and counted using a Coulter Z2 Particle Counter. 1
x 106 cells were aliquoted into pre-labeled Falcon 2008 tubes for each stain to be
performed.
Surface staining. Surface proteins were detected using a standard protocol. Briefly,

ali quoted cells were washed once with FACS® media (HBSS with 0.1 % BSA, 0.1 %
Sodium Azide, and 0.036% Sodium Bicarbonate), and spun as described. The
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supernatant was poured off, cells were resuspended in 100 JlL of FACS® media, and 20
JlL of the appropriate antibody dilution was added (see below for antibody dilutions).
The cells were incubated for 20 minutes at 4°C in the dark, washed once with F ACS®
media and placed on ice.
Fixing and intracellular/intranuclear staining. After surface staining and washing,
cells were washed once with phosphate buffered saline without calcium or magnesium
(PBS-), then resuspended in 100 JlL ofPBS-. A vial of 16% formaldehyde (Polysciences
catalog #18814) was opened, and a 4% solution was made by dilution into PBS-; the
formaldehyde stock was discarded. 100 JlL of 4% formaldehyde was added to each tube
of cells while gently vortexing. The cells were covered with aluminum foil and
incubated on ice for 3 hours. Cells were washed twice with PBS-, and resuspended in
100 JlL of stain buffer (PBS- plus 5% FBS and 0.5% TritonX-100). The cells were
covered and incubated on ice for 30 minutes, after which time 20 JlL of the appropriate
primary antibody dilution was added. The cells were gently mixed and incubated on ice
for 30 minutes, covered. Cells were washed once with stain buffer, resuspended in 100
JlL of stain buffer, and 20 JlL of secondary antibody was added. The cells were covered
and incubated on ice for 30 minutes. Finally, cells were washed with stain buffer and
resuspended in 250 JlL of stain buffer for data acquisition. All solutions were kept on ice.
Permeabilization and staining of unfixed cells. Cells were aliquoted and washed with
FACS® media as described for surface staining and resuspended in 100 JlL of FACS®
media with 0.03% saponin (F ACS plus saponin) (22). 20 JlL of the appropriate primary
antibody was added to each tube, and the cells were incubated at 4°C in the dark for 30
minutes. Cells were washed once with FACS plus saponin, and resuspended in 100 JlL
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of FACS plus saponin. 20 J..lL of the appropriate secondary antibody dilution was added,
and the cells were incubated for 30 minutes at 4°C in the dark. Finally, cells were
washed once with FACS plus saponin and once with FACS® media. The cells were
resuspended in either 250 J..lL of FACS® media or 250 J..lL of nuclear isolation media
(NIM; FACS® media plus 1 mM EDTA and 0.5% NP-40). All wash steps were in 2 mL
of media.
Antibody panels and dilutions and flow cytometry. Surface staining was performed

using anti-CD4 (RM4-5)-APC and anti-CD8 (53-6.7)-PE, both from Pharmingen.
Antibodies were diluted together into FACS® media, with a dilution factor of 1: 100 for
each antibody. For intracellular/intranuclear staining, antibodies were diluted using the
permeabilization buffer appropriate for the method and were used at the following
dilutions: goat polyclonal anti-GFIl (sc-8558, Santa Cruz Biotechnology) at 1:10, goat
polyclonal anti-GFIlB (sc-8559) at 1:50, and normal goat IgG (sc-2028) at 1:25 and
1:125 for GFIl and GFIlB controls, respectively; rabbit polyclonal anti-EGR1 (sc-189)
at 1:200 (23), and normal rabbit IgG control (sc-2027) at 1:400. Dilution factors for IgG
control antibodies were based on the final J..lg quantity of the experimental antibody used.
Secondary antibodies, bovine anti-goat FITC (sc-2348) and donkey anti-rabbit FITC
(711-096-152, Jackson Laboratories), were used at a 1:100 dilution. Anti-BCL2-FITC
and its FITC conjugated isotype control (catalog #554221, BD Pharmingen) were used at
a 1:33 dilution. Flow cytometry was performed on a Becton Dickinson FACSCaliburTM
flow cytometer, and analysis was performed using FlowJoTM (TriStar) software.
Fluorescence Microscopy. Green fluorescence protein (GFP) transgenic mouse

thymocytes were sorted to >95% purity for positive GFP fluorescence on a FACS
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Vantage Cell Sorter (Becton Dickinson) using 488 nm excitation and standard FITC
emission optics. 700,000 sorted thymocytes were stained with 5 uM Hoechst 33342 in
FACS® media for 30 minutes at 37°C. Stained cells were divided into two equal parts,
pelleted, and resuspended in 100 ilL of F ACS® media or NIM. A wet mount of 50 ilL of
each sample was analyzed for GFP (cytoplasm) and Hoechst fluorescence (nuclei) on an
Olympus IX50 fluorescence microscope.

Results and discussion.

BeL2 and EGRI confirm valid fixation of surface stain and permeabilization.
We were interested in using flow cytometry to detect nuclear transcription factors
that are expressed at low levels within thymocyte subsets. We started with commercially
available antisera to the GFIlB transcription factor. Though unfixed GFIlB transgenic
thymocytes showed GFIlB-positive staining when permeabilized with 0.03% saponin,
we were unable to detect positive staining if cells had been fixed in a solution of 1%
formaldehyde (Polysciences catalog #04018) in HBSS despite attempts to permeabilize
with 0.03% or 0.3% saponin, and 0.1 % or 0.5% TritonX-100 (22;23). We therefore
purchased an EM-grade formaldehyde (Polysciences catalog #18814) that is supplied in
individual 10-mL aliquots. The formaldehyde was stored in the dark, and a vial was
opened immediately prior to use. The unused portion was discarded, limiting the
exposure of the reagent to light and to oxidizing substances in the air. By so limiting the
degradation of the formaldehyde, we decreased the autofluorescence of the fixed cells
(25), thereby increasing our signal-to-noise ratio and allowing detection of transcription
factors in thymocyte subsets.
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To ensure the accuracy of our results, we examined proteins with established
expression patterns and cellular localization. By confirming the known expression
profile ofBCL2 (26) (Figure 4), we were able to determine that our fixation and
permeabilization methods do not disturb antigen-antibody interactions. Moreover,
detection of the nuclear transcription factor EGRI (27) using the same protocol served as
a control for permeabilization of the nuclear membrane (Figure 4). In sum, our
adaptation of established permeabilization and fixation techniques allows sensitive and
accurate detection of intranuclear antigens without disrupting membrane or cytoplasmic
staining.
GFIlB is not detectable in most thymocytes of wild-type mice. In fact, utilization
of the sensitive methods described here allowed detection in only the relatively rare
CD44- DN subsets (19). Therefore, wild-type thymocytes served as negative controls for
staining with anti-GFIlB (data not shown), further confirming the specificity of our
reagents and methods.
Isolation and analysis of nuclei confirm nuclear localization of transcription factors.
For our experiments it was necessary to confirm nuclear localization of our
transgenic transcription factors. To accomplish this task, we adapted a method that has
historically been used to study nuclei for DNA content (24).
Unfixed cells were permeabilized and stained as described, then resuspended in
either FACS® media or NIM for the isolation of nuclei. The removal of the cytoplasm
was confirmed separately by microscopic analysis of sorted GFP-positive thymocytes
that had been stained with the DNA dye Hoechst 33342 and resuspended in either FACS
or NIM (Figure 5), and for stained cells by a change in forward and side scatter properties
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Figure 4. Intracellular/intranuclear staining of fixed thymocytes. Shown is a
representative F ACS plot of surface-stained, fixed, permeabilized and intracellularly
stained thymocytes. Gates are drawn around each of the four major subsets, and are
labeled as DN (double negative), DP (double positive), CD8 (CD8 single positive), and
CD4 (CD4 single positive). The expression of BCL2 and EGRI was examined by
intracellular/intranuclear staining and the results are shown in histogram format. In each
histogram overlay, the dotted line represents staining with the control IgG and the solid
line represents the experimental stain. As expected, BCL2 is expressed highly in CD4,
CD8, and most DN cells, and at low levels in DP cells. A positive shift in fluorescence in
the presence of the anti-EGRI antibody occurred in all thymocyte subsets, though the
range of expression level is larger in DN thymocytes as indicated by a broader histogram.

- 26-

Figure 4
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(data not shown). Permeabilized and stained cells and nuclei were analyzed by flow
cytometry for a positive shift in fluorescence intensity. Figure 5 shows histogram plots
of cells (top) versus nuclei (bottom) for BCL2, EGRl, GFIlB, and GFIl (left to right).
Each histogram overlay includes both the experimental stain (solid bold line) and the
corresponding IgG control (dashed line). The stains for BCL2 and EGRl were
performed using wild type thymocytes, while those for GFIlB and GFIl were performed
using thymocytes from mice that were transgenic for GFIlB or GFIl, respectively.
BCL2, which localizes to the mitochondria, was included as a cytoplasmic control.
Total thymocytes (cells) show variable expression of BCL2, mirroring the expression
profile in thymocyte subsets. However, isolated nuclei do not show any positive staining
for BCL2, as the mitochondria are removed with the cytoplasm during the nuclear
isolation step. Results are shown for EGRl, GFIlB, and GFIl. The intensity of signal
for an intranuclear stain depends on both the affinity of the antigen/antibody interaction
and the abundance of the protein within the nucleus of a cell. The slight shifts for GFIlB
and GFIl, both expressed from transgenes, is likely due to a relatively low affinity of the
polyclonal antibodies available to detect them. In all stains performed, the overall shifts
of both the IgG control and the experimental stain decrease upon isolation of nuclei,
likely due to a loss of autofluorescence from cytoplasmic proteins. However, the stain
for each transcription factor retains its shift above background in intact nuclei, while the
shift for BCL2 disappears. Taken together, these data suggest that flow cytometry is a
reliable method for determining nuclear localization of proteins.
We have developed and described companion methods for l) detecting poorly
expressed proteins in subsets of heterogeneous cell populations using low-affinity
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Figure 5. Retention of nuclear stains upon removal of cytoplasm and cellular
membrane. Microscopic analysis of Hoechst-stained GFP-positive thymocytes
confirmed removal of cytoplasmic contents upon resuspension in NIM. The FACS
image (cells) represents merged GFP/ Hoechst fluorescence while the NIM image is only
the Hoechst fluorescence. No GFP fluorescence was observed in isolated nuclei.
Histogram overlays indicate the expression of BCL2, EGRI, GFIlB, and GFIl, (left to
right) in total thymocytes. The overlays include the specific IgG control for the
experimental antibody (dashed line) and the experimental stain (bold line). Plots for
intact cells are shown above plots for isolated nuclei. The nuclei are negative for BCL2,
but positive for EGRI, GFIlB, and GFIl. Note: Microscopy performed by Michael K.
Tanner, Institute for Cellular Therapeutics, University of Louisville.
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Figure 5
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polyclonal antibodies and 2) confirming nuclear isolation of transcription factors. These
methods combine to provide simple, reliable, and fast alternatives to traditional methods.
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CHAPTER III
GFIlB EXPRESSION LEADS TO DEFECTS IN T-CELL ACTIVATION, IL7-Ra
EXPRESSION AND T-CELL LINEAGE COMMITMENT

Introduction.
T cell differentiation in the thymus is dependent upon signaling through the T
Cell Receptor (TCR) and is characterized by the resulting changes in expression patterns
of CD4 and CDS surface coreceptor molecules. Early thymocyte precursors are CD4"
CDS" (double negative, DN) and are signaled to differentiate first into CD4+CDS+ (double
positive, DP) thymocytes. Further differentiation ofDP thymocytes into mature CD4+S"
single positive (CD4 SP) or CD4"S+ (CDS SP) T cells is triggered by the engagement of
TCRs on the immature TCRhiCD4+CDS+ thymocytes by self-peptidelMHC complex on
thymic epithelial cells (2S;29). Negative selection eliminates immature DP thymocytes
through clonal deletion of those T cells that have high affinity for self peptide and thus
are potentially autoreactive (30). Positive selection occurs when low-affinity TCRligand interactions trigger a signal for survival and results in termination of one or the
other CD4 or CDS coreceptor molecule. The choice of which coreceptor to extinguish is
referred to as lineage commitment.
The Growth Factor Independence-l (GFIl) and GFIlB proteins are closely
related nuclear oncoproteins that may regulate cytokine pathways. Gfil was originally
identified as the gene upregulated by insertion of Moloney murine leukemia virus
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(MoMLV) in a thymic lymphoma that was selected for its ability to grow in the absence
of the T-cell cytokine IL-2 (8). Forced expression ofGFIl in the IL-2-dependent
parental cell line potentiates the outgrowth oflL-2 independent cell lines, without
inducing IL-2 (8;9). Gfil B was identified by low stringency hybridization screening with
a cDNA probe encoding the zinc-fmger region of Gfil (10). GFIl and GFIlB are 97%
homologous in the carboxy-termina1165 amino acids that code for six Cys-His zincfingers. An amino-terminal 20-amino-acid SNAG domain, responsible for nuclear
localization and transcriptional repressor function, is also highly conserved (9). In
contrast, the 236 intervening amino acids between the GFIl SNAG and zinc-finger
domains bear no homology to the corresponding 145 amino acids ofGFIlB. Both
proteins bind to virtually identical DNA consensus sequences and function as
transcriptional repressors in a SNAG-dependent manner (9;10). GFIl is mildly antiapoptotic and inhibits growth arrest ofIL-2 dependent T cell lines under conditions of
limiting IL-2 (9;31), while GFIlB inhibits both IL-6-induced differentiation and growth
arrest ofMl myelomonocytic cells (10). Mice deleted for Gfil have altered
inflammatory responses and differentiation in the myeloid lineage (17), while mouse
embryos deleted for Gfil B die in utero due to a lack of definitive erythropoiesis (18).

Gfil and GfilB are differentially expressed in lymphoid compartments. Northern
analysis reveals that Gfil is expressed in the bone marrow and thymus, with low-level
expression in the spleen, whereas Gfil B is expressed in the bone marrow and spleen, with
low-level expression in the thymus (10). Both Gfil and GfilB show regulated expression
during T cell development, but Gfil B expression is terminated in mature thymocytes.

Gfil message is not expressed in Go splenic T cells, but is induced upon T cell activation
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(8;20). Transgenic expression ofGFIl and GFIlB in T cells allowed us to determine the
functional basis for differential expression of these factors. Transgenic expression of
GFIl potentiates T-cell activation. In contrast, ectopic expression ofGFIlB in T cells
results in defective T-cell activation, lower numbers of peripheral T cells, a reduction in
IL-7Ra expression and a developmental block to CD8 SP T cells. The block to CD8 SP
development is mitigated by forced expression of BCL2 or GFIl. These data indicate
that GFIl and GFIlB are not redundant for T cell activation function, and implicate
integration of activation and survival signaling in CD8 lineage commitment.

Materials and Methods.
Mice. The generation of the ed2-Gfil transgenic mice has been described (20). The lekGfil transgenic mouse (line 3A) was generated by cloning the rat Gfil cDNA into the
BamBI site of the TLC vector (32). This vector contains a 3.2-kb fragment of the mouse
lek proximal promoter and a 2.2-kb fragment of the human growth hormone (GH) gene,
which provides exons and introns for splicing and polyadenylation sequences. A 2.2-kb
fragment of the 3' locus control region of the human CD2 gene is located downstream of
the GB to obtain copy-number- and insertion-site-independent levels of expression. The
GFIIB transgenic mice (lines 5B and 5C) were constructed in an identical manner to the
GFIl transgenic except the construct contained the cDNA for mouse Gfil B inserted into
the BamBI site. The GFIl and/or the GFIlB transgene (1 to 5 nglJ.lI) was microinjected
into C57BLl6J (Jackson Laboratory) eggs according to standard methodology in the
Laboratory of Immunopathology, NIAID, NIH.
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RAG2-1-IHY mice (Taconic), and EJ-l-BCL2-25 transgenic mice (Jackson
Laboratory) (33) were purchased from commercial vendors. All mice were on a
C57BLl6 J background and bred in the Baxter Barrier animal care facility at the
University of Louisville School of Medicine and housed under specific pathogen-free
conditions. GFIl and GFIlB transgenic daughters who were heterozygous for the RAG
mutation, as well as the HY TCR transgenes were then backcrossed with their RAG2-1-,
HY TCR+ fathers. Colonies were expanded by intercrossing oflittermates. BCL2/GFIlB
and cd2-GFIl/GFIlB bi-transgenics were generated in a similar manner. All animal
work performed was reviewed and approved by the University of Louisville Institutional
Animal Care and Use Committee.
Antibodies. Antibodies with the following specificities were used for cell stimulations:
CD3E (l45.2Cll) and CD28 (37.51). Antibodies with the following specificities were
used for staining of thymocytes and splenocytes: CD4 (RM4-5 and GK1.5), IL-7Ra.
(A7R34; eBiosciences), CD8a (53-6.7), CD3E-( 145-2Cll), TCR-a~ (H57-597), TCR
V~8

(F32), CD24a-(Ml/69), CD69 (H1.2F3), and CD25 (PC61). Antibodies were

purchased from BD-Pharmingen unless otherwise noted. Intranuclear staining was
performed using anti-GIFIB goat polyclonal IgG (sc-8559), anti-GFIl goat polyclonal
IgG (sc-8558), normal goat IgG (sc-2028) control, and secondary bovine anti-goat IgGFITC (sc-2348), all from Santa Cruz Biotechnology.
Preparation of Cell Suspensions. Thymi from 4- to 6- week-old mice were removed
and disrupted between frosted ends of glass slides and washed twice with Medium 199
(Gibco BRL Life Technologies, Gaithersburg MD). Cells were obtained from spleens by
perfusion with 10 ml Medium 199. Both thymocyte and splenocyte cell debris was
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depleted by passage through Nytex nylon mesh screens. Splenocytes were treated with
ammonium chloride-potassium bicarbonate (ACK) solution (150mM NH4CI and 10 mM
KHC03) to lyse red blood cells. For experiments requiring isolation ofT cells, splenic
cell preps were depleted of other cell types by the use of T cell enrichment columns
(R&D Systems). All cells were counted with a Coulter Counter model Z2 (Coulter,
Miami FL) and viability assayed by trypan blue exclusion.

Flow Cytometric Analysis. Cell surface staining was performed by incubating 1x 106
cells with mAbs at varying concentrations in FACS® media (HBSS with 0.1 % BSA,
0.1 % Sodium Azide, and 0.036% Sodium Bicarbonate) for 20 min on ice. Stained cells
were washed twice with FACS® media and fixed in 1% formaldehyde (Polysciences,
Warrington, PA). For intracellular staining, cells were fixed in 2% formaldehyde in PBS
and permeabilized and stained in PBS + 5% fetal bovine serum and 0.5% Triton x-tOO.
Flow cytometry was performed on a FACSCaliburTM, FACSVantageSE, or FACStar
flow cytometer using standard CELLQuestTM acquisition. Data were analyzed using
CELLQuestTM (Becton Dickinson) and FlowJoTM (TreeStar) software. The absolute
cell numbers of gated cells per thymus or spleen were calculated by multiplying the
percentage of each population with the total number of cells per thymus or spleen
respectively.

Northern, Western and RT-peR Analyses. RT-PCR analyses were performed as
previously published (34;35). The sequences of the Gjil-specific primers were 5'CACACCTTCATCCACACAGG-3',5'-GATGAGCTTTGCACACTGGA-3', and the
probe was 5'-TACCGTGAGGATGTCTTCCC-3'. The sequences of the GjilB-specific
primers were 5'-AGCACAGAGTCTCCCTTGGA-3', 5'-
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CAAAGGTTTTGCCACAGACA-3', and the probe was 5'ACCCCTCATGGGCTAGAAGT-3'. The GfilB pattern was confirmed with the primers
5' -GAGCAGCATACTCACGTCCA-3', 5'-TTCATGTCCGACTTCTGGTG-3', and the
probe was 5'-CAAAGCCTTCAAGCGTTCAT-3'.
Western blotting with antibodies against GFIl (sc-6357), GFIlB (sc-8559, Santa
Cruz)), GFIl and GFIlB (sc-6357), p27 (BD Pharmingen 554069) and IRF1 antibody
(sc-640) was performed as follows. Single cell suspensions of primary thymocytes were
lysed at a concentration of 10-20 x106 cells/lOOJ,l1 SDS lysis buffer (25 mM Tris pH 7.5,
10% glycerol, and 2% SDS supplemented with Protease Inhibitors Complete (Roche) and
2mM PMSF. Protein concentration was determined using the BCA Protein Assay
Reagent (Pierce, Rockford IL), and 75 J,lg of cellular extract was run on a 10% SDSpolyacrylamide gel, transferred to Immobilon-PVDF (Millipore, Bedford, MA) and
blocked for 1 hour at room temperature (RT) in blocking buffer (5% milk, 20 mM Tris,
pH 7.3, 6.85 mM NaCi, 0.1 % (v/v) Tween-20, 0.5 gIL MgCI2). Membranes were
incubated overnight at 4°C in primary antibody diluted in 5% protease-free BSA (Fisher
Biotech, Pittsburgh, PA), then HRP-conjugated secondary antibody (Amersham) for one
hour at RT. Blots were developed using ECL reagents (Amersham,). For Western
analysis of sorted thymocytes and purified T cells, 1x106 cells were resuspended in 15 J,ll
of lysis buffer (50 mM HEPES pH 7.8, 450 mM NaCI, 0.2 mM EDTA, 25% glycerol, 1%
NP40 (36), Protease Inhibitors Complete (Roche), and 2 mM PMSF), then sonicated
using a Misonix Sonic Dismembrator with microprobe tip. 4X loading buffer was added,
and the lysates were boiled. The entire contents of the lysate were loaded onto a
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denaturing SDS polyacrylamide gel, and Western blotting was performed as described
above.
Cell Stimulation and Proliferation. Single cell suspensions of spleen cells in RPMI

1640 (Gibco BRL Life Technologies, Gaithersburg, MD) supplemented with 5% fetal
bovine serum, L-glutamine, penicillin, streptomycin, gentamycin, 2% HEPES (all from
Gibco BRL Life Technologies) and 0.1% 2-mercaptoethanol (Sigma) were plated in 96well round-bottom plates (Corning, Corning, NY) at a density of lxlO 5 per well in 100

,.11. Stimuli were added as indicated at a range of concentrations to assess dose
dependency. The stimuli were low-endotoxin, no-azide anti-CD3 (145.2Cll), anti-CD28
(37.51) (both antibodies from Pharmingen, San Diego, CA), and recombinant human IL2 (Chiron, Emeryville, CA). Cells were cultured for 48 or 72 hours, then pulsed with
eH]thymidine (I~Ci) (Amersham, Piscataway, NJ), and harvested 18 hours later using a
TOMTEC-Harvester961 Model Mach II (Wallac, Akron, OH). Proliferation was
determined by measuring radioactivity (Wallac 1205-SP2 Betaplate Counter).
Coreceptor Reversal. Purified DP thymocytes (>96%) were obtained by panning with

IgM anti-CD8 (83-12-5) coated plates. DP thymocytes (5 x 106/ml) were first placed into
"signaling cultures" and stimulated for 12-18 hours with a combination ofphorbal-12myristate-13-acetate (0.6 nglml) and ionomycin (0.6

~glml)(P+I;

Calbiochem) (37). At

the conclusion of signaling culture, cells were harvested, washed, and placed into
nonstimulatory "recovery cultures" for an additiona112-16 hr. Cells were stained for
CD4 and CD8 expression and CD4+CD8- cells were obtained by electronic sorting of the
stained cells. The purified CD4+8- cells were further cultured in "postrecovery cultures"
in the presence or absence of 6 nglml recombinant mouse IL-7 (Calbiochem, San Diego,
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CA) overnight, after which they were harvested and stained for CD4 and CD8
expression. All cultures were performed at 37°C in 5% C02 humidified air atmosphere
in RPMI 1640 supplemented with 5 x 10-5M 2-mercaptoethanol and 10% FCS that had
been depleted of endogenous steroids by pretreatment with 0.5% Norit A charcoal and
0.05% dextran for 30 min at 56°C.

Results.
Gftl and GftlB are regulated during T lymphopoiesis.
We examined the steady-state mRNA levels ofGji1 and Gji1B during T
lymphopoiesis (Figure 6A). Thymocyte populations were sorted, RNA was extracted,
and reverse transcriptase-polymerase chain reaction (RT-PCR) was performed to detect
ribosomal S16 expression (34;35). The products of the reaction were analyzed by
Southern blot with a radiolabelled 816-specific oligonucleotide probe. The signal was
quantified by phosphorimager, and the samples were normalized to obtain equivalent 816
signal from each template. Subsequent analysis of Gji1 expression in the 816-normalized
cDNA templates revealed low-level signal in CD4"CD8-CD44+CD25- cells (DN1) and 10
fold greater levels in CD4"CD8-CD44+CD25+ (DN2) thymocytes. The transition between
DNI and DN2 corresponds to T lymphocyte lineage commitment. Signal intensity from
the Gji1 RT-PCR product gradually increases to double the DN2leveis at the
CD4+CD8+TCRhi stage, which contains cells that have been recently positively selected
and are about to undergo lineage commitment. Gji1 RT-PCR product levels then
decrease 10 fold in CD4 and CD8 single positive thymocytes. In striking contrast, the
signal levels of probed and quantified Gji1B RT-PCR product were low, but increased at
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Figure 6. Expression of endogenous GFIl and GFIlB. A. Blotted and probed RTPCR analyses of Gfil and Gfil B in reverse-transcribed thymocyte-subset eDNA
templates. eDNA templates were normalized for equivalent signal from blotted, probed
S16. Primer/probe pairs for Gfil and GfilB were applied to the normalized eDNA
templates to determine the relative Gfil and GfilB RT-PCR product levels in thymocyte
subsets. Note: These data were generated by Dr. Sabine Herblot and Dr. Trang Hoang
(Research Institute of Montreal, Montreal, Quebec) using PCR primers and conditions
designed and optimized by Loretta Doan. B. Western blot analysis of sorted thymocyte
subsets. 1 x 106 sorted cells of each subpopulation were lysed, and the total lysate was
probed with anti-GFIl (top panel) or anti-p27 (bottom panel) as a loading control. GFIl
protein levels are moderate in DP thymocytes and intermediate CD4+CDS lo cells, but
increase in mature CD4 and CDS SP cells. Note: These data were generated jointly by
Loretta Doan and Dr. Mary Kate Kitay. C. Flow cytometric analysis ofGFIl expression
in thymocyte subsets. Intranuclear staining of surface stained fixed thymocytes yielded
an expression profile for GFIl similar to that observed in C. Specifically, the level of
GFIl protein increases in SP thymocytes. The pattern of GFIl expression in DN
thymocytes has been published (36). D. Flow cytometric analysis of GFIlB expression
in thymocyte subsets. Intranuclear staining of surface stained fixed thymocytes revealed
expression of GFIlB in the relatively rare CD4-CDS-CD44- populations of cells. The
average change in mean fluorescence intensity is indicated below each graph, and is
defined as

~MFI=(MFIGFIlBIMFIIgG)xlOO

(+/-SEM). GFIlB transgenic CD4-CDS-CD44-

thymocytes have a higher MFI in comparison to WT cells; whereas RAG2"'- thymocytes,
which lack TCR signaling (3S), do not express detectable levels ofGFIlB.
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stages corresponding to T cell receptor beta-chain selection (DN3), and positive selection
(DP TCRhi ). In the thymus, Gfil expression is gradually induced upon induction of the T
cell differentiation program, whereas low-level Gfil B expression correlates with positive
selection events.

GFIl and GFIlB are expressed in normal thymocytes.
To examine the level ofGFIl in thymocyte subsets we performed Western
analysis on one million sorted DP, CD8 SP, CD4 SP and CD4+CD810 thymocytes (Figure
6B). The level ofGFIl does not differ between the bulk ofDP thymocytes and those
poised to make a lineage commitment step (CD4+CD8 iO); however, the level of GFIl is
dramatically higher in SP thymocytes. To confirm these data, we examined thymocyte
expression ofGFIl by intranuclear staining and flow cytometry. As seen in the Western
blot data, flow cytometric analyses revealed higher levels of GFIl protein in SP
thymocytes (Figure 6C). The upregulation ofGfil message in DP thymocytes, with
subsequent increase in GFIl protein in SP cells, suggests that GFIl may playa role in the
transition between these two developmental stages.
RT -PCR analyses revealed restricted expression of Gfil B in relatively rare
thymocyte subsets (Figure 6A). Not surprisingly, Western analysis and intranuclear
stains for GFIlB failed to reveal GFIlB expression in bulk thymocytes (data not shown).
Therefore, we focused on a flow-cytometric analysis of the relatively rare CD44- DN3
and DN4 thymocytes that appear to express the highest levels of Gfil B message (Figure
6A). We first examined the DN3 and DN4 cells from GFIlB-transgenic mice (detailed
below). A comparative 66% shift in mean fluorescence intensity (~MFI =
MFIGFIlS/MFIIgG x 100) between the control IgG antisera and GFIlB-reactive antisera
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indicates that GFIlB protein is present (Figure 6D). In a similar manner, analysis of the
DN3 and DN4 cells from non-transgenic littermates revealed a 41 % shift in MFI between
control and GFIlB-specific antisera stains (Figure 6D).
The RT-PCR data (Figure 6A) indicate that GfilB expression correlates with
positive selection events. To explore this correlation we examined thymocytes from

RAG2-1- mice, which are arrested at the DN3 stage because they lack the pre-TCR
selection signal that follows RAG-mediated rearrangement of the TCR-beta chain. Flowcytometric analyses reveal no difference in MFI between control and GFIlB-reactive
antisera in RAG2-1- thymocytes (Figure 6D). These data indicate that signals from the
pre-TCR may be required for GFIlB expression.

Transgenic Expression of GFIl and GFIlB.
GFIl and GFIl B bind the same DNA sequence and repress transcription in a
manner dependent on the SNAG repressor domain (9; 10), suggesting the possibility that
these factors are redundant. High-level transgenic expression of GFIl in the thymus
results in a block to T cell development at a stage corresponding to selection of cells after
successful formation of the

TCR~

chain (36). Given the thymic phenotype ofGFIl

overexpression, we constructed transgenic mice expressing GFIl or GFIlB in developing
and mature T cells (Figure 7A). Transgene-specific Northern analysis revealed that
GFIl-transgenic founders had moderate expression while GFIlB-transgenic founders had
higher levels of expression; representative lines are shown (Figure 7B). Western analysis
of total thymocytes and of column-enriched splenic T cells indicates that the transgenic
GFIlB protein is expressed in both the thymus and the periphery (Figure 7C). Finally,
flow cytometric analysis of the GFIIB-transgenic thymocyte populations revealed
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Figure 7. Expression of transgenic GFIl and GFIlB. A. Schematic representation of
the GFIl- and GFIlB-transgene constructs. The rat cDNA ofGfil (8) and mouse cDNA
of GfilB (10) was placed under the control of the lckproximal promoter and 2.2kb
human CD2 enhancer, with human growth hormone (GH) gene (32). B. Northern blot
analysis of total thymus or spleen RNA from representative GFIl (line 3A) and GFIlB
(line 5B) transgenic lines hybridized with transgene-specific probes. Total RNA from
transgenic animals revealed moderate levels of transgenic Gfil in both thymus and
spleen, while transgenic GfilB is expressed at higher levels. C. Western blot analysis of
transgenic GFIl B in thymic or column-purified splenic T-cell whole-cell protein extracts.
Cell extracts from 2 control (WT) and 2 GFIlB-transgenic mice were analyzed by
Western blot with an antibody specific for the last 20 amino acids of GFI 1 (cross reactive
to GFIlB). Densitometric analysis revealed that transgenic GFIlB is expressed at fivefold higher levels than is endogenous GFIl in non-transgenic littermate thymocytes.
Lysates probed with antiserum against IRF-l act as a control for loading. D. Flow
cytometric analysis of GFIlB expression in GFIlB-transgenic thymocyte subsets.
Transgenic expression of GFIlB is observed in all thymocyte subsets, though the level of
expression is somewhat lower in CD8 SP cells.
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transgenic GFIlB expression in DN, DP, CD8 SP and CD4 SP thymocytes (Figure 7D).
To explore the subcellular localization of transgenic GFIl and GFIlB, the
cytoplasm of permeabilized and stained thymocytes was removed using NP40. Stripping
the cytoplasm resulted in a loss of signal for the mitochondria-localized BCL2, but did
not alter the 8MFI ofthymocytes stained for GFIl or GFIlB (data not shown), indicating
that the targets of the respective antisera are nuclear. Given that these antisera are specific
for GFIl and GFIlB in Western analysis, our flow cytometric data indicate that
transgenic GFIl and GFIl B are localized to the nucleus of T cells.
Transgenic expression of GFIl enhances T cell response to CD3 crosslinking and
IL-2.

GFIl was previously shown to confer IL-2 independence to rat T-cell lymphomas
(8;31). IL-2 is a critical T-cell cytokine during activation, and though peripheral
lymphocytes do not express detectable levels of Gfil, activation signals induce Gfil
within 30 minutes (20). Moreover, transgenic expression of GFIl was previously shown
to mildly increase eH]-thymidine uptake given a fixed amount of CD3 crosslinking
antibody (20). To further examine the effect of GFIl on T-cell activation potential,
spleen cells from 4-6 week-old mice were stimulated by titration of a CD3-crosslinking
antibody. T cells from mice expressing GFIl from either the Lck-promoter driven
transgene (Figure 7A), or a previously published CD2-promoter driven transgene (20),
proliferated at a higher rate than T cells from control mice as evidenced by enhanced
eH]-thymidine uptake (Figure 8A) and by increased numbers of cells in each cellular
division as evidenced by CSFE staining (data not shown).
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Figure 8. GFIl potentiates, whereas GFIlB inhibits, T-cell activation. A and B.
Spleen cells from 4-6 week old GFIl transgenic mice (line 3A or a CD2 promoter-driven
GFIl transgenic (20)) and nontransgenic littermate control mice were isolated and
stimulated with either a dose titration of plate-bound antibody to CD3E (A) or a low level
of anti-CD3E (0.06 J..lglml) and increasing amounts of human rIL-2 (B) and cultured for
48 hours. eH] thymidine (1 J..lCi) was added and plates were incubated for 18 hours.
Proliferation was measured as CPM of eH] thymidine incorporation. Error bars indicate
standard error of the mean. Note: These data were generated by Dr. Michael Alexander.
The results shown in Panel A were reproduced by Loretta Doan. C. Spleen cells from 46-week-old GFIl transgenic mice, as well as littermate controls, were stained with
antibodies to CD4 and CD8 then analyzed by flow cytometry. A representative FACS
profile is shown. No difference was observed in total number of splenocytes or in splenic
T cell numbers between GFIl transgenics and littermate controls of either line. Note:
These data were generated by Dr. Mary Kate Kitay and reproduced by Loretta Doan. D.
Spleen cells from 4-6 week old GFIlB transgenic mice (lines 5B and 5C) were activated
as in (A) for either 48 hours (left panel) or 72 hours (right panel) before the addition of
eH] thymidine. E. Spleen cells isolated from 4-6-week-old GFIlB transgenic line 5B,

as well as littermate controls, were stained with antibodies to CD8 and CD4 and analyzed
by flow cytometry. A representative FACS profile is shown. Absolute spleen cell
numbers from all mice examined were determined and are expressed in the table below as
cell numbers x 10 6 ± SEM in the table below. Note: These data were generated by Dr.
Mary Kate Kitay and reproduced by Loretta Doan.
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To dissect the response ofGFIl-transgenic splenic T cells to stimulation, we
limited the amount of CD3 antibody, and added increasing amounts ofIL-2. Again, we
found that cells from GFIl-transgenic mice proliferated more vigorously in response to
stimulation than cells from non-transgenic littermates (Figure SB). A flow cytometric
analysis of splenocytes from control and GFIl transgenic mice show equivalent absolute
cell numbers of total splenocytes and T cell subsets as delineated by the markers CD4,
CDS, TCR beta, and CD3E (Figure SC), or CD62L and CD44 (data not shown).
Therefore, GFIl potentiates the response to CD3 and IL-2 stimulation.
GFIlB transgenic mice display peripheral T lymphopenia and a profound defect in
activation after CD3 cross-linking.
We next looked at the response of GFIl B transgenic splenic T cells to stimulation
with anti-CD3E and found that they neither died (data not shown), nor proliferated
substantially. Spleen cells from 4-6 week-old mice from two GFIlB-transgenic lines (SB
or SC, Figure SD) were stimulated by addition of increasing quantities of a CD3crosslinking antibody. T cells from GFIlB transgenic mice proliferated at a substantially
lower rate than T cells from control mice as evidenced by eH]-thymidine uptake, even
when the activated cells were given an additional 24 hours incubation (Figure SD, 4S
hours versus 72 hours).
An unanticipated potential explanation for this observation came from the finding
that spleen cells from GFIlB transgenic mice show significant reduction in the numbers
of CD4 and CDS T cells that could respond to CD3 stimulation (Figure SE). Mature CD4
cells were reduced to 32% of wild type levels, while mature CDS cells were reduced to
46% of wild type levels (Figure 8E). However, neither the TCR-expression level on
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splenic T cells (data not shown) nor the total number of splenocytes (Figure 8E) was
significantly reduced in GFIlB transgenic mice. Since both the GFIlB-transgenic lines
gave equivalent data, we focused on the 5B line for further studies.
The unresponsiveness of GFIlB lymphocyte populations to TCR-mediated
activation signals could be due either to T lymphopenia or to a defect in signaling. To
determine the mechanism, T cells were purified by negative selection, normalized to
CD38+ T-cell numbers, and stimulated simultaneously with both anti-CD38 and antiCD28 in a co-receptor activation assay. Co-stimulated GFIlB-transgenic cells showed a
marked inability to proliferate as compared to cells from non-transgenic littermates
(Figure 9A). In addition, GFIlB-transgenics demonstrated decreased proportions of cells
expressing activation markers CD69 and CD25 (IL-2 receptor a-chain) as compared to
wild type cells (Figure 9B), as well as a decrease in fluorescence intensity of these
markers on positive cells (data not shown). Therefore, GFIlB transgenic T cells are
profoundly impaired in response to activation signals because of an intrinsic signaling
defect, and not because of the overall reduction in CD38+ T cell numbers. These data are
diametrically opposed to our findings for GFIl-transgenic mice, which showed enhanced
response to activation.

Transgenic GFIlB expression alters thymocyte lineage commitment and
maturation.
In order to determine the cause of peripheral T lymphopenia, we examined the
thymus. Thymocytes were stained with antibodies against CD4, CD8, and TCR~ and
analyzed by flow cytometry. In GFIlB transgenic mice, the number ofCD4 SP cells was
considerably enhanced while there was a severe reduction in the development of CD8 SP
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Figure 9. The GFIlB-induced inhibition of activation is cell autonomous and
includes defective upregulation of early activation markers. A. 4 week old GFIlB

transgenic and control splenic T lymphocytes were purified by negative selection,
normalized for numbers of CD3+ T cells, and then co-stimulated with antibodies to CD3E
and CD28. Proliferation was measured by eH] thymidine incorporation and the
stimulation index (fold induction over non-stimulated controls) was calculated. A
representative of 3 experiments is shown. Note: These data were generated by Dr.
Michael Alexander. B. Splenocytes from GFIIB transgenic (open symbols, black
background) and littermate controls (closed symbols, white background) were stimulated
with antibodies to CD3 for 24 hours then stained with antibodies to CD4, CD8, CD25
(circle) and CD69 (diamond) and analyzed by flow cytometry. CD4+or CD8+ events
were gated, and the percentages ofCD25+ or CD69+ cells are depicted. Fewer GFIIBtransgenic splenocytes exhibit induction of either CD25 or CD69. Bars = mean. Note:
These data were generated by Amy Barber Schonck and reproduced by Loretta Doan.
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Figure 10. Transgenic expression of GFIlB in the thymus results in enhanced
numbers of mature CD4+ thymocytes and decreased CDS+ populations. A and B.
Thymocytes from GFIIB transgenic and controllittermates were stained with antibodies
to TCR~, CD4, and CD8, and analyzed by flow cytometry. The average number of total
thymocytes x 106 ± SEM is expressed above the plots, with percentage of cells in each
gate in (A). In (B) cells are gated on TCRint-hi events, and the CD4 versus CD8 FACS
6

profiles are depicted. Thymocyte subsets are expressed as absolute cell numbers x 10
per thymus ± SEM. Note: These data were generated by Dr. Mary Kate Kitay and

reproduced by Loretta Doan. C. Thymocytes from 4-week-old GFIlB transgenic and
controllittermates were stained with antibodies to CD24a, CD4, and CD8 and analyzed
by flow cytometry. FACS profiles depicted are gated on CD4+ events. Absolute
thymocyte cell numbers from all mice examined were determined and are expressed as
cell numbers x 106 ± SEM. Note: These data were produced jointly by Loretta Doan and
Dr. Mary Kate Kitay.
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T cells (Figure lOA). The CD8 SP compartment contains both mature and immature
intermediate single positive cells (CD8 ISP). CD8 ISP cells, in contrast to CD8 SP cells,
do not have high level TCR expression. Therefore, the analysis was repeated through a
TCRint-hi gate, which would include CD4 SP, CD8 SP thymocytes and their immediate
precursors (39). The ratio of CD4+ to CD8+ cells was increased in the TCRint-hi
population from a normal ratio of7:1 to a ratio of32:1 in the GFIlB-transgenic mice
(Figure lOB). Therefore, few mature CD8 SP cells are generated in the GFIlB transgenic
mice. Moreover, the lower numbers of CD8 SP cells provides a potential explanation for
peripheral CD8 lymphopenia.
We next examined the CD4 SP population. As CD4 SP thymocytes mature they
downregualte CD24IHSA and exit the thymus. Therefore, the most mature CD4 SP
thymocytes express low levels of CD24 and are relatively rare in wild type mice, while
less mature CD4 SP thymocytes express higher levels of this marker (39-41). We found
that the number of immature CD4 SP thymocytes (CD24hi) was relatively normal in
GFIlB-transgenic mice; however, the number of mature CD4 SP thymocytes was
increased five fold (Figure 10C). These data are supported by the surface expression of
TCR~,

Qa-2 and CD62L (data not shown), which also indicate that GFIlB-transgenic

mice have greater numbers of phenotypically mature CD4 SP thymocytes. We have also
examined the effects of the GFIlB transgene on a class II MHC null background to find
that no CD4 SP cells were generated (data not shown). These data exclude the possibility
that the increased CD4 SP cells are due to redirection ofMHC-class-I-restricted CD8 SP
development into the CD4lineage. Altered signaling during activation in GFIlB
transgenic thymocytes may lead to the accumulation of cells which should not normally

55

be selected (defective negative selection), or the accumulation of cells unable to mature
and egress.

The development of CDS SP T cells in GFIlB transgenic mice is not rescued by
expression of the HY Class I restricted trans gene.
It is unlikely that GFIlB represses CD8 or MHC class I expression since

thymocytes from GFIIB-transgenic mice reveal normal surface expression ofCD8u and
CD8~

in the DP fraction, and are not Class I-deficient (data not shown). To determine if

the GFIlB block to CD8 development involved an alteration in TCR repertoire selection,
GFIlB transgenic mice were mated to RAG2-1-/HY mice and resulting progeny were
backcrossed to generate GFIlBI RAG2-1-/HY mice. The HY trans gene encodes a Class Irestricted TCR that selects large numbers ofV~8+ thymocytes into the CD8+ T cell
lineage in female mice (42). Because the Rag2 gene product is necessary for TCR
rearrangement, all RAG2-1-/HYIGFIl B transgenic thymocytes express only the HY TCR
as evidenced by V~8 staining (data not shown). Positive selection ofCD8+ T cells by the
HY TCR was severely reduced in the RAG2-1-/HY/GFIlB female mice as compared to
controls (Figure 11). Therefore, the critical defect in GFIl B transgenic mice is not
simply an inability to form a class I restricted TCR.

GFIlB expression overcomes a block to DP development imposed by autoreactive
TCR signaling.
To determine ifGFIlB-transgenic thymocytes display defective TCR signaling
and/or activation in vivo we next examined the male RAG2-1-/HY/GFIlB mouse thymus.
The HY TCR recognizes the male HY antigen when presented by H2-Db. Male HY
transgenic thymocytes are blocked at the DN stage by auto-reactive HY TCR signaling
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Figure 11. Expression of GFIlB inhibits the development of female HY-transgenic
CDS SP T cells. Thymocytes from 4 week-old female RAG2-1-/HY and RAG2-1IHYIGFIl B mice were examined for the expression of CD4, CDS, and TCR V~S

(utilized in the HY trans gene) by flow cytometry. Representative FACS plots are shown
with the total number ofRAG2-1-/HY and RAG2-1-/HY/GFIlB thymocytes above the
6

plots. Thymocyte subsets are expressed as absolute cell numbers X 10 per thymus ±
SEM. Note: These data were generated by Dr. Mary Kate Kitay.
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that mimics negative selection (43). Mutant mice with defective intracellular signaling
overcome this block and accumulate V~8+ DP cells (44-46). GFIlB-transgenic
peripheral T cells are defective in T-cell activation (Figures 8D and 9A).

In agreement

with these data, GFIlB-transgenic thymocytes overcome the block to development
imposed by the autoreactive HY transgene, as shown by a modest four-fold accumulation
ofCD8+ TCR~+ cells (11.1 % versus 47.9%) and a doubling of total thymus cellularity
(Figure 12A and 12B). Therefore, our in vitro and in vivo data support a model in which
ectopic expression of GFIlB leads to defective T cell activation.

GFIlB impairs CD8 SP development in vitro, and decreases IL-7Ra expression.
We have previously described an in vitro model system in which DP thymocytes
can be signaled to differentiate into CD8 SP T cells (37). In this experimental system,
signaled DP thymocytes initially terminate CD8 transcription, differentiate into CD4+8intermediate thymocytes, and upregulate surface expression of IL-7R. In the presence of
IL-7, CD4+8- intermediate thymocytes terminate CD4 transcription and re-initiate CD8
transcription (events referred to as 'coreceptor reversal') and ultimately differentiate into
CD8 SP T cells (37). Consequently, we assessed the ability of signaled DP thymocytes
from wildtype (WT) and GFIlB transgenic mice to differentiate in vitro into CD8 SP T
cells (Figure 13 A).
We isolated WT and GFIlB transgenic DP thymocytes (Figure 13A, Do) and
stimulated them with phorbal-12-myristate-13-acetate (PMA) and ionomycin (P+I) as
previously described (37). Signaled DP thymocytes from both WT and GFIlB transgenic
mice were induced to differentiate into CD4+8- intermediate cells (Figure 13A, D2).
Notably, in vitro generated intermediate CD4+8- cells from GFIlB transgenic mice
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Figure 12. Expression of GFIlB overcomes a block to development in male HYtransgenic T cells. Representative FACS plots showing expression of CD4 and CDS (A)
or CDS and TCR V~S (B) in male HY transgenic mice. Male RAG2-1-/HY/GFIlB mice
show a 4-fold increase in the number ofCD4+CDS+ and TCR V~S+ thymocytes when
compared to RAG2-1- HY littermates. The total numbers ofRAG2-1-/HY and RAG2-1/HY/GFIlB thymocytes are shown above the plots. Note: These data were generated by

Dr. Mary Kate Kitay and re-analyzed by Loretta Doan.
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Figure 13. GFIlB impairs co-receptor reversal. A. (DO) Purified CD4+CD8+ cells
were obtained from pooled thymocytes of four 4-week-old GFIlB transgenic or four
controllittermates by panning with anti-CD8 antibody, and subsequently stimulated with
PMA and ionomycin (P+I) for 16 hrs at 37°C. Stimulated cells were stripped of their
surface coreceptors with pronase protease, cultured in complete media overnight, stained
for CD4 and CD8 expression and purified CD4+8- cells were obtained by cell sorting.
(D2) Control (dashed line) and GFIlB transgenic (solid line) cells were analyzed by flow
cytometry for IL-7Ra expression. Purified CD4+8- cells (2 x 106) were cultured
overnight in the presence of IL-7.

Flow analysis of samples of each culture indicated

CD4 and CD8 surface levels before (D3) and after pronase protease treatment and culture
in complete media overnight (D4). Note: These data were generated by Dr. Qing Yu
and Dr. Alfred Singer (Experimental Immunology Branch, National Cancer Institute,
National Institutes of Health, Bethesda, MD 20892). B. Four week old GFIlBtransgenic (solid line) and normallittermate control (dashed line) thymocytes were
stained with antibodies against CD4, CD8 and IL-7Ra and analyzed by flow cytometry.
Representative histograms comparing the IL-7Ra expression in thymocyte
subpopulations are shown. Note: These data were generated jointly by Loretta Doan and
Dr. Mary Kate Kitay.
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expressed lower surface levels ofIL-7Ra compared to cells from WT mice (Figure 13A,
D2). We then added IL-7 to both populations of in vitro generated intermediate CD4+Sthymocytes, and, after 24h, pronase stripped the cells to remove pre-existing CD4/CDS
surface proteins so that we could determine the CD4/CDS proteins that the cells were
actively synthesizing. Addition of IL-7 (Figure 13A, D3) followed by pronase stripping
and re-expression culture revealed that 69.3% ofWT cells had undergone coreceptor
reversal and differentiated into CDS SP T cells. In contrast, only 21.0% ofGFIlB
transgenic cells had undergone coreceptor reversal to become CDS SP T cells (Figure
13A, D4). Thus, GFIlB transgenic thymocytes at the CD4+S- intermediate stage of
development are quantitatively deficient in their ability to undergo coreceptor reversal in
response to IL-7 and are impaired in their ability to undergo in vitro differentiation into
CDS SP T cells.
To determine if the lower in vitro expression pattern of IL-7Ra on GFIl B
transgenic thymocytes was a possible explanation for the defective CDS SP development

in vivo, we next examined the expression of IL-7Ra in unmanipulated thymocytes. Cells
were stained for CD4, CDS and IL-7Ra, then gated on thymocyte subpopulations and
analyzed for IL-7Ra expression (Figure 13B). The level of IL-7Ra on DN thymocytes
was not altered by the presence of the GFIlB transgene. However in both CD4 SP and
CDS SP thymocytes, in which IL-7Ra expression is regulated by TCR signaling, GFIlB
transgenic mice had lower levels of IL-7Ra than wild type littermate controls (Figure
13B). Thus, GFIlB transgenic thymocytes are defective in both T cell activation and the
expression of activation-induced genes such as CD25, CD69 and IL-7Ra. The lower
level ofIL-7Ra on GFIlB transgenic thymocytes provides a potential explanation for
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altered CD8 SP development in the GFIlB transgenic mice. Moreover, examination of
peripheral T cell subsets revealed lower levels of IL-7Ra (data not shown). Since IL-7
has been shown to regulate the survival of naIve CD4 T cells (47-50) the lack ofIL-7Ra
expression is a possible explanation for peripheral CD4 T cell lymphopenia.

Bi-transgenic BCL2/GFIlB mice generate CDS SP thymocytes.
GFIlB-transgenic thymocytes express lower levels ofIL-7Ra (Figure 13B). IL-7
maintains the expression of endogenous BCL2 in T-lineage cells (51). BCL2 does not
support thymic positive selection in the absence ofMHC (52-54); however, transgenic
expression of BCL2 can substitute for survival signals induced by cytokines such as IL-7
(54). GFIlB-transgenic mice were mated to

E~-BCL2-25

transgenic mice, in which the

human BCL2 trans gene is expressed mainly in T lineage cells (33). As expected by the
presence of the BCL2 transgene, total thymocyte cellularity was increased in bitransgenic mice (33); however, we found that BCL2/GFIlB bi-transgenics show
increased numbers of TCRint-hi CD8 SP thymocytes and a normal ratio of CD4 SP to CD8
SP thymocytes (Figure 14). While BCL2 may have pleiotropic effects on T-cell
development (53), the ability ofBCL2 to rescue CD8 SP development in GFIlBtransgenic mice is consistent with the role of BCL2 as a downstream target of IL-7.

Bi-transgenic GFIl/GFIlB mice generate CDS SP thymocytes.
We next determined whether GFIl could alter the defects engendered by GFIlB
expression. GFIl enhances T cell activation whereas GFIlB impairs this process (Figure
8). Since GFIl and GFIlB bind to the same DNA sequence, it is possible that some of
the defects in GFIlB transgenic thymocytes are the result of an imbalance between DNAbound GFIlB versus GFIl. In fact, six-week-old GFIl/GFIlB bi-transgenic mice
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Figure 14. Transgenic BCL2 restores CDS SP thymocytes in GFIlB transgenic
mice. Thymocytes from GFIlB and BCL2/GFIlB bitransgenic littermates were stained

with antibodies to TCRP, CD4, and CD8, and analyzed by flow cytometry. Cells are
gated on TCRint-hi events, and representative CD4 versus CD8 FACS profiles are
depicted. A scatter plot ofCD8 SP cells in BCL2-transgenic, GFIlB-transgenic, and
BCL2/GFIlB-bitransgenic mice reveals the increase in the CD8 SP population in the
bitransgenic animals (in comparison to GFIlB-transgenic mice). Each diamond
represents the percent of TCRint-hi CD8 SP cells per thymus of an individual mouse (5-7
mice/group). The black bar is the mean value for each group. Note: These data were
generated by Dr. Mary Kate Kitay and re-analyzed by Loretta Doan.
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Figure 15. Transgenic GFIl increases the generation of CD8 SP thymocytes in
GFIlB transgenic mice. Thymocytes from 6-week-old GFIlB and GFIl/GFIlB bitransgenic littermates were stained with antibodies to TCRP, CD4, and CD8, and
analyzed by flow cytometry. Cells are gated on TCRint-hi events, and representative CD4
versus CD8 FACS profiles are depicted. A scatter plot of CD8 SP cells in GFIltransgenic, GFIlB-transgenic, and GFIl/GFIlB-bitransgenic mice shows the partial
restoration of CD8 SP thymocytes observed in bi-transgenic animals (in comparison to
GFIl B-transgenic mice). Each diamond represents the percent of TCRint-hi CD8 SP cells
per thymus of an individual mouse (4-6 mice/group). The black bar is the mean value for
each group. The increase is statistically significant with a P value of 0.0003 as
determined using a two-tailed Student's T test.
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generate twice as many TCRint-hi CD8 SP thymocytes than do littermate GFIlB
transgenics (Figure 15, P = 0.0003). The lower level of expression of the GFIl transgene
in comparison to the GFIl B transgene may explain the modest ability of GFIl transgene
to compete with transgenic GFIlB. Nevertheless, GFIl expression increases the number
of GFIlB-transgenic CD8 SP cells.
Transgenic expression of GFIl does not alter other GFIlB-induced defects. The
GFIlB-induced abnormal generation of phenotypically-mature CD4 SP thymocytes
remains in the GFIl/GFIlB bi-transgenic thymus. Moreover, peripheral T lymphopenia
in GFIlB transgenics is not altered by BCL2 or GFIl. It is known that BCL2-transgeneinduced elevation in thymocyte numbers does not alter peripheral T cell numbers (51).
Likewise, we find that neither BCL2 nor GFIl increases the number of peripheral CD8
SP T cells in the GFIl B-transgenic spleen. GFIl, like BCL2, appears to ameliorate only
the GFI 1B effect on the production of CD8 SP cells. The inability of either the BCL2 or
GFIl transgene to cancel the GFIlB-induced alteration in the expression ofIL-7Ra (data
not shown) indicate that both BCL2 and GFIl must act to increase CD8 SP generation by
a mechanism that is independent of the induction of IL-7 signaling. However, it is
formally possible that GFIl, like BCL2, acts downstream of IL-7 signaling and that
transgenic expression of either protein mimics the effects of IL-7.

Discussion.
The phenotypes observed in GFIl and GFIlB transgenic mice can be understood
in the context of the normal expression pattern of either factor. GFIl is induced at the
transition between DP and SP cells. GFIl may thus playa role in the activation-induced
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developmental steps between DP and SP thymocytes. GFIlB is induced at steps in
thymocyte development in which thymocytes are activated. In fact, RAG2-1- cells that
lack the ability to activate do not express GFIlB (Figure 6). GFIl and GFIlB have
opposite effects on T cell activation. Peripheral GFIl transgenic T cells activate better
than do those from wild type littermates, whereas GFIlB transgenic T cells are impaired
in activation. Both phenotypes are cell autonomous as they occur in purified T cells from
either transgenic (Figure 9 and data not shown).
The impairment ofT cell activation function in GFIlB transgenic T cells appears
to be linked to an inability to signal properly after TCR engagement and costimulation.
First, purified GFIlB-transgenic T cells do not activate given CD2S- and CD3crosslinking antibodies (Figure 9A). Second, the TCR-signaling-dependent RASIMAPKinduced expression of early activation markers CD25 and CD69 (55) is impaired in
GFIlB transgenic T cells (Figure 9B). Finally, in male HY transgenic mice GFIlB
expression rescues the generation ofDP thymocytes that are normally deleted due to
strong autoreactive TCR signals (43). Similar results have been obtained in male HY
transgenic mice that are rendered defective in TCR signaling by deletion of intracellular
proteins that participate in the TCR-signaling cascade (44-46). However, the GFIlBinduced defect in T cell activation cannot be restricted to proximal signaling molecules in
the TCR- and costimulatory-signaling pathways, since GFIlB-induced impairment of
CDS SP cell formation is also observed after in vitro drug-stimulated activation that
bypasses the need for proximal TCR- and costimulatory-signaling events (Figure 13).
The ability of GFIlB-transgenic thymocytes to respond to cytokine signaling may also be
affected. Though activated GFIl B transgenic thymocytes fail to induce IL-7Ra
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expression, transgenic expression ofIL-7Ra (56) did not change the GFIlB induced
phenotypes (data not shown), whereas expression of the IL-7 downstream effector BCL2
increased CD8 generation. Thus, GFIIB expression in T cells induces cell autonomous
defects in intracellular signaling that may impair T cell activation at multiple steps.
GFIl B may serve as a negative regulator of GFIl-enhanced activation. Both
GFIl and GFIlB are expected to repress genes to alter the kinetics or activation potential
of intracellular signals. The induction ofGFIlB in activated thymocytes could result in
competition between GFIl and GFIlB for DNA binding at specific promoters.
Alternatively, GFIl and GFIlB may regulate different promoters. Both scenarios appear
to be relevant to the GFIlB-induced T cell defects. Since transgenic GFIl expression
doubles the generation ofGFIlB-transgenic CD8 SP cells, GFIl and GFIlB may
compete at promoters to regulate genes important for CD8 development. Target genes
responsible for this phenotype may be properly regulated by GFIl, but improperly
regulated by GFIlB in cells about to undergo lineage commitment. Interestingly,
transgenic BCL2 or GFIl rescued CD8 SP development, but did not affect GFIIBinduced changes in CD4 SP development, the expression of IL-7Ra or peripheral T
lymphopenia. Target genes responsible for the latter GFIlB-induced phenotypes should
be independent of GFIl regulation and instead uniquely regulated by GFIlB.
GFIl and GFIlB differ in amino acid sequence in the region between the SNAG
repressor domain and the zinc-finger DNA-binding domain. These dissimilar regions
may mediate interaction with other proteins (such as other transcription factors or adapter
proteins), leading to differential regulation of target promoters by GFIl and GFIlB. The
normal role of GFI I B in the thymus may be to regulate the extent of GFI I-mediated
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thymocyte activation during development. Our data are the first to demonstrate that GFIl
and GFIlB are not redundant for T cell activation functions, providing a potential
biological explanation for the termination ofGFIlB expression in mature T cells.
IL-7 is critical for the survival and proliferation of immature thymocytes into
mature CD8 SP cells (37;54;57). IL-7 is constitutively present in the thymus; however,
IL-7Ra expression is not induced until TCR stimulation ceases (37). Thus, whether TCR
signaling continues or ceases determines the ability to differentiate into CD8 SP T cells.
This new perspective on lineage commitment is referred to as the "kinetic signaling"
model. In accordance with this model, GFIlB-transgenic thymocytes, in which GFIl
function is compromised, fail to integrate activation signals, resulting in impaired
expression of activation-induced survival genes such as IL-7Ra (37).
Models of lineage commitment which require quantitative or temporal differences
in TCR signals to direct T cell development (58;59) would predict that the reduced
activation in GFIl B-transgenic T cells should lead to improved CD8 SP development
(60). Transgenic expression ofGFllB in the thymus instead results in a severe decrease
in the generation of CD8 SP cells. A similar phenotype is exhibited by mice made
deficient for interferon a,p signaling by knocking out the transcription factor IRF-l (61).
These mice are devoid of CD8 SP T cells even though they contain normal numbers of
CD4 SP T cells. We have established that the GFIlB-transgenic thymus defects are not
due to GFIlB repression ofIRF-l (Figure 7C), CD8 or MHC Class I (data not shown),
the absence of a functional TCR rearrangement (Figure 11) or to a TCR-signalindependent redirection of CD8 cells to a CD4 lineage choice (data not shown).
However, in agreement with the kinetic signaling model, a signal-independent survival
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cue from the downstream target of IL-7, BCL2, increases CD8 SP generation in the
context ofGFIlB expression. Therefore, the defect in generation ofCD8 SP cells in
GFIlB-transgenic mice appears to be linked to an inability to transduce a post-activation
signal-dependent survival cue.
GFIl functions to inhibit T cell death induced by specific stimuli; GFIl increases
survival of explanted thymocytes (62) and decreases apoptosis induced by TCR ligation
(21). In GFIlB transgenic T cells, GFIl expression does not correct GFIlB-impaired
expression ofIL-7Ra; however, like BCL2, transgenic GFIl increases CD8 SP
generation in the GFIlB transgenic thymus. The salient function of GFIl in CD8 SP
generation may be GFIl mediation of cytokine induced survival signaling that is impeded
in GFIlB transgenic thymocytes. Taken together, these data are the first to suggest a role
for GFIl in the integration of activation signals from the TCR with survival signals from
cytokines such as IL-7.
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CHAPTER IV
GFIl IS AUTOREGULATORY IN T CELLS, BUT NOT IN A MYELOID
LINEAGE CELL LINE

Introduction.

Growth Factor Independence 1 (G.fil) and G.filB are two closely related
oncogenes that play different but pivotal roles in hematopoiesis. G.fil deficient mice
display both thymic and peripheral T lymphopenia, with severe abnormalities in pre-T
cell development (11; 16; 17). Furthermore, they display a profound defect in neutrophil
differentiation, which leads to neutropenia (16;17). G.filB is necessary for the
development of megakaryocytes and for definitive erythropoiesis (18). Deficiency of

G.filB is embryonic lethal by day E15 (18). Given embryonic lethality, no thymic or T
cell phenotype has been reported for G.filB deficiency; however, GFIlB transgenic mice
display perturbed T cell development and function (19). In accordance with the distinct
hematopoietic phenotypes of G.fil and G.fil B deficiency, normal adult animals express
these two factors in a tissue-specific manner (10). G.fil is predominantly expressed in
thymus, the site of T cell development, while G.fil B is expressed in spleen. Both factors
are expressed in bone marrow (10).
The unique physiological functions of G.fil and G.fil B may seem somewhat
surprising given the similarities oftheir defined biochemical and oncogenic
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functions (9;10). GFIl and GFIlB are two members ofa family of zinc-finger
transcriptional repressors that are characterized by the presence of the SNAG (found in
the Snail and Gfi 1 family of proteins) repression domain (9). Transcriptional repression
by both GFIl and GFIlB requires an intact SNAG domain. Specifically, in in vitro
transient transcription assays, SNAG activity can be abrogated by mutation of the Proline
at position 2 to Alanine (P2A) (9). Furthermore, GFIl and GFIlB have been shown to
bind very similar consensus DNA sequences, both of which have an absolute requirement
for the tetranucleotide sequence AATC (10). Mutation of this AATC core to GGTC
results in a lack of DNA binding in vitro (15). Despite the extensive similarities of these
proteins, each contains a region unique in amino acid sequence, the activities of which
are yet to be defined.
We and others have reported that in T cells, transgenic expression ofGFIl causes
an increase in the response to TCR-stimulated activation (19-21). Conversely, we have
shown that GFIlB is induced during T lymphopoiesis at stages involving activation, and
that transgenic expression of GFIl B in T cells leads to decreased activation (19). These
effects were seen in both mature T cells in vitro and in thymocytes in vivo. While GFIlB
transgenic mice display normal thymic cellularity, they share with Gfil deficient mice the
characteristic of peripheral T lymphopenia. In addition, GFIIB transgenics display
thymic abnormalities, including a defect in the formation of CDS SP cells, which can be
partially corrected by transgenic expression ofGFIl(19). Thus, some of the observed
GFIl B-mediated effects on T lymphopoiesis may result from the disruption of normal
functions ofGFIl (19). We therefore sought to determine the mechanism by which
GFIl B interferes with GFIl activity.
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Upon comparison of expression levels of the transgenic GFIl and GFIlB, we
discovered that endogenous GFIl is not expressed at detectable levels in GFIlB
transgenic thymocytes. Given the roles ofGFIl and GFIlB as transcriptional repressors,
we hypothesized that transgenic GFIlB represses the transcription of endogenous Gjil.
In this report, we show that mouse, rat, and human Gjil are repressed by both GFIl and
GFIlB, and that this repression is both direct and dependent on the SNAG repressor
domain in vitro and in vivo. In addition, we identify in vitro GFIl binding of consensus
recognition sequences in regulatory regions of the Gjil gene, and suggest previously
undefined sequence requirements for binding by GFIl in nuclear complexes.
Furthermore, we provide evidence that GFIl autoregulation may be a cell-type-specific
mechanism, occurring in primary T cells and a T cell line, but not in a myeloid lineage
cell line.

Materials and methods.
Mice. The GFIl and GFIlB transgenic mice were previously described (19). P2A-GFIl

transgenic mice were generated similarly by cloning the P2A-GFIl-mutant cDNA into
the BamHI site of the TLC vector (32). All mice were housed in the Donald Baxter
Barrier Facility at the University of Louisville and used in accordance with protocols
approved by the U ofL Institutional Animal Care and Use Committee.
Plasmids. Plasmids used in transient transcription assays were previously described (9).

Plasmids for in vitro transcription and translation were generated by cloning rat Gjil,

LlZn4Gjil, or mouse Gjil B into the pcDNA3 vector (Invitrogen). Retroviral vector
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expression constructs were generated by cloning triple Flag-epitope-tagged GFIl and
mutant GFIl (SV40swap) (9) into the MIEV vector (63).
Transfections, transduction, and transcription assays. For stable transfections, lurkat
cells were electroporated as previously described (9). TLC transgene constructs encoding
GFIl or GFIlB were co-transfected with empty pcDNA3.1 vector DNA at a ratio of22:1.
Transfected cells were selected in the presence of ImglmL Geneticin (Invitrogen) and
cloned by limiting dilution.
293T cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM)
with 10% FBS, 1% L-Gln, 1% PenlStrep (Invitrogen). Cells were transfected with
Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol using OptiMEM low serum medium (Invitrogen) and 2.5 x 10 5 cells/well in 24-well plates that were
pre-coated with poly-L-Lysine (0.1 mg/mL, Sigma). Transfections were performed in
triplicate. CAT assays were performed as previously described (9). A 2-tailed Student's
T test determined P values.
For transduction experiments, Phoenix cells (64) were transiently transfected with
retroviral constructs using calcium phosphate (Ca3(P04)2) (65) then co-cultured with
U937 cells overnight. The transduced U937 cells were expanded and sorted on a
FACSV antage (BD); sorted GFP+ cells were analyzed after two weeks in culture.
Northern and Western blot. For Northern blots, total RNA was extracted using
Ultraspec RNA Isolation Solution (Biotecx Laboratories, Inc. Houston, TX) according to
the manufacturer's protocol, and poly-A+ RNA was obtained using Oligotex Direct
mRNA purification protocol (Qiagen Inc., Valencia, CA). Total RNA (20llg) or Poly A+
RNA (5Jlg) was electrophoresed in a 1% agarose-formaldehyde gel and transferred to
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MagnaGraph nylon membrane (Micron Separations, Inc., Westboro, MA). Membranes
were probed in UltraHyb solution (Ambion, Austin, TX) according to the manufacturer's
protocol. Radioactive probes were generated by Prime-I-Gene random priming kit
(Promega, Madison, WI).
Western blot detection ofGFIl and GFIlB was performed as previously
described (19). Nuclear extracts ofU937 cells were made using NE-PER (Pierce)
according to manufacturer's instruction, and protein concentration was determined using
BCA Protein Assay Reagent (Pierce). Primary antibody was either a commercially
available antiserum to the last 20 amino acids of GFIl (Santa Cruz, sc-6357), anti-FlagHRP (Sigma), or a mouse monoclonal to GFIl (2.5D.17).
RNase and DNase. For resolution of the sequence of the rat locus, primer extension was
performed with an end-labeled oligonucleotide complementary to exon I sequence,
hybridized to 50llg total RNA from rat Nb-2lymphoma cells or normal rat thymus, and
the reaction products were analyzed by electrophoresis through a 7% polyacrylamidel7M
urea sequencing gel.
To characterize the exon-intron boundaries and genomic organization of Gfil, an
F344 rat genomic AD ash clone (8) was digested with EcoRI and the resulting fragments
subcloned in pBluescript SK (Stratagene, Valencia, CA). Next, oligonucleotide primers
based on the Gfil cDNA sequence were used to probe Southern blots of the genomic
subclones, for PCR amplification, and for sequencing.
Cultures were harvested, and nuclei were isolated and subjected to incremental
DNase I digestions as previously described (66).
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Electrophoretic mobility shift assays (EMSA). Shifts were performed essentially as
described (14). In vitro transcription and translation (IVT) was performed using TNT
T7-coupled reticulocyte lysate system (Promega) according to the manufacturer's
protocol. Jurkat nuclear extracts (NE) were prepared using a standard Dignam protocol
(67). The sense sequence of the -705 probe is 5'GGAGCAAACCTCAGGGATTGGGTGTCAAGGTA-3', and the mutant probe is 5'GGAGCAAACCTCAGGGACCGGGTGTCAAGGTA-3'. The underlined bases were
added for labeling using Klenow (NEB) and a)2 P-dCTP (Amersham, Piscataway, NJ).
NE (2.5 ug) or IVT protein (3 to 5 uL) was pre-incubated in binding buffer (14) at room
temperature for 20 minutes, with cold oligonucleotide or antibodies [anti-GFIl (sc-8558)
or normal goat antiserum (sc-2028)] for competition and super-shift assays. Labeled
probe (50,000 cpm) was added, and the reaction continued at room temperature for 30
minutes. Samples were electrophoresed through a 6% non-denaturing polyacrylamide
gel, which was dried and exposed to film.
ChIP. ChIP assays were performed as previously described (13). Each experiment was
performed twice with similar results, and representative data are shown.

Results.
Endogenous murine Gftl is repressed by transgenic expression of GFIl or GFIlB in
primary thymocytes.
Transgenic expression of GFIlB engenders defects in T lymphopoiesis, some of
which can be rescued by simultaneous forced expression of GFIl (19). Because GFIl
and GFIlB have nearly identical DNA binding domains (10), we reasoned that GFIlB
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may alter T lymphopoiesis by competing with endogenous GFIl for DNA binding on
specific promoters. However, Western blot analysis of whole celllysates from GFIlBtransgenic thymocytes revealed undetectable levels ofGFIl protein (Figure 16A). These
results led us to investigate the levels of endogenous Gfil transcript in GFIl and GFIl Btransgenic thymocytes. Since the transgenes lack the Gfil 3' untranslated region, we
performed Northern analysis with a murine Gfil 3' -untranslated-region probe on polyA+-selected RNA from GFIlB-transgenic thymi. These analyses revealed a dramatic
reduction in the level of endogenous Gfil transcript (Figure 16B). Moreover, transgenic
mice with forced low-level expression of GFIl display a mild reduction of endogenous

Gfil message (Figure 16B). Therefore, GFIlB-transgenic T cells are essentially devoid
ofGFIl, and Gfil may be targeted for repression by both GFIl and GFIlB.

The SNAG-repression-domain mutant P2A-GFIl profoundly de-represses
endogenous murine Gfil.
The P2A-GFIl mutation significantly impairs GFIl-mediated repression (9).
Therefore, we predicted that the P2A-GFIl mutant would act as a dominant-negative and
interfere with GFIl function. We constructed transgenic mice in which P2A-GFIl is
expressed in T cells through the Lck proximal promoter and a CD2 enhancer (Figure
16C) (32). Deletion of Gfilleads to a significant decrease in thymocyte numbers and
impairs T lymphopoiesis (11;16;17). However, contrary to our expectation of dominantnegative GFIl activity by the P2A-GFIl mutant, thymi ofP2A-GFIl-transgenic mice
display no discernable phenotype (data not shown). Northern analysis ofthymus RNA
with a transgene-vector-specific probe revealed adequate expression of P2A-Gfil

81

Figure 16. Endogenous murine Gfil is repressed by GFIl and GFIlB in
thymocytes. A. Western blot analysis of protein (75 ug) from thymocyte whole cell
lysates of two wild type (WT) and two GFIlB transgenic mice. The blots were probed
with an antibody against the last 20 amino acids of GFIl that is cross-reactive to GFIlB
(sc-6375). A loading control (IRFl) is shown. B. Northern blot analysis ofpoly-A+
RNA (5 Jlg). Endogenous Gfil was detected using a probe specific to the 3' untranslated
region of mouse Gfil. Blots were stripped and probed with a loading control (MDM2).
Note: These data were generated by Dr. H. Leighton Grimes and Loretta Doan. C.
Diagram of the transgene construct used in creating P2A-GFIl transgenic mice. The
transgene vector(32) is identical to that utilized to create GFIl and GFIlB transgenic
animals. D. Northern blot analysis of total RNA (20 ug) from thymocytes of two wild
type (WT) and two P2A-GFIl (P2A) transgenic mice using the same probe as in B.
Ethidium bromide staining is shown for equal RNA loading.
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message (data not shown). We subsequently performed Northern analysis ofP2Atransgenic thymocytes with the murine Gfil 3' untranslated region probe. This analysis
revealed a striking de-repression of endogenous Gfil in the presence oftransgenic P2AGFIl (Figure 16D). Whereas in normal thymocyte RNA the detection of Gfil requires
poly-A+ selection (Figure 16B), the Gfil signal in P2A-transgenic thymocyte RNA was
easily detected by Northern blot analysis of 20 Jlg of total RNA (Figure 16D). The
profound de-repression of endogenous Gfil in repression-defective P2A-GFIl-transgenic
thymocytes is evidence for direct autoregulation of Gfil.
Identification of the rat Gft1 promoter.
Given the probability of direct repression of Gfil, we next wanted to examine the

Gfil promoter for GFIl/GFIlB DNA-binding sites. However, the sequence of the Gfil
promoter had not been well resolved. Early identification of Gfil as an oncogene was
performed in rat T cell leukemia lines, providing a biological impetus for studying the
transcriptional regulation of rat Gfil. Genomic clones from the rat locus were analyzed
by restriction endonuclease digestion, followed by Southern blotting with Gfil cDNA
probes and sequencing. We determined both the exonlintron boundaries of the gene
(Figure 17A), and the organization of the rat Gfillocus (Figure 17B). Specifically,
examination of the sequence of intronlexon boundaries revealed the presence of 7 exons
and 6 introns. The exonlintron boundary sequences are homologous to the previously
published mouse locus (68), with minor exceptions. The genomic organization of rat

Gfil is diagramed in Figure 17B and spans 9.5 kb of sequence. These data were
corroborated by the recently available rat genomic sequence in GenBank (data not
shown).
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Figure 17. Characterization of rat Gfillocus and identification of the transcription
start site. A. Exonlintron boundaries of rat Gfil. Shown are the splice donor and
acceptor sites as determined by sequencing. B. Schematic representation of the
organization of the rat Gfillocus. Exons 1-7 are depicted as gray boxes. Arrows identify
DNase hypersensitive sites, with the longest arrow representing the start site of
transcription. Roman numerals indicate probes used for DNase hypersensitivity analysis.
C. Southern blot analysis of DNase hypersensitivity assays. Nuclei from Nb2 (lanes 1-4
ofleft panel), A2 (lanes 5-8 ofleft panel), or LE3Spi (right panel) rat cell lines were
digested with increasing concentrations of DNAse I, the DNA was digested with HindIII
restriction endonuclease, and Southern blots were hybridized with probes I and II.

AIHindlII molecular weight markers are indicated on the left of each blot. The arrow
indicates the major site of hypersensitivity, corresponding to the longest arrow in panel
B. Minor bands represent other regions of putative transcriptional control corresponding
to smaller arrows in panel B. D. RNase protection assay identifies the start site of
transcription. The left panel shows representative results of RNase protection analysis
from rat Nb-2lymphoma cells (1) and normal rat thymus (2). Arrows indicate the major
protected fragments and the corresponding nucleotides on a sequencing gel. The right
panel depicts the sequence of the start site and the consensus sequence of an Inr. Note:
All of these data were generated by Dr. C. Blake Gilks and Dr. Susan D. Porter
(Department of Pathology and Genetic Pathology Evaluation Centre, Vancouver General
Hospital and the University of British Columbia).
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To determine potential regulatory regions, DNase hypersensitivity assays were
performed (Figure 17C). Analysis of rat Nb2 and A2 lymphoma cells using a genomic
probe (Figure 17B, I) revealed hypersensitive sites clustering around exon 1 (arrows in
Figure l7B). Many of these sites occur within the first intron, but the major site of
DNase hypersensitivity is just upstream of the first exon (longer arrow Figure l7B, and
arrow Figure 17C). In LE3Spi cells, two downstream hypersensitive sites were also
identified using probe II and are indicated in Figure 17B. The same pattern was seen
with both probes with or without prolactin addition to prolactin-dependent Nb2 cells, and
with or without Interleukin-2 addition to the Interleukin-2-dependent LE3Spi cell line
(data not shown).
We next mapped the start site of transcription of the rat Gfil gene. The mouse

Gfillocus has both a major transcription start site 5' of exon la, and a minor one in the
first intron (68). Therefore, we performed RNase protection analysis to locate the
transcriptional start site(s) in the rat Gfil gene. In RNA from rat Nb2lymphoma cells, a
sequence proximal to exon 1 was identified as the single start site of transcription in the
rat Gfil gene (Figure l7D). This sequence (TCAGAGC, Figure l7D) corresponds to the
consensus sequence of an initiator element (Inr) (69). Inr elements are commonly
utilized as transcription start sites in TATA-less lymphoid-specific genes such as TdT
(70). In agreement with this, we found no evidence of a canonical TATA box in the
sequence of this region. Moreover, the relative position of the Inr corresponds to the
major site of DNaseI hypersensitivity. In contrast to both mouse and human Gfil which
generate mUltiple sized transcripts, the rat locus generates a single transcript (8). No start
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sites were detected in the first intron of the rat gene (data not shown). Thus, the Oftl rat
locus appears to have a single start site corresponding to a consensus Inr sequence.

Mouse and human Gfilloci contain sequences homologous to the rat Gfil promoter
including conserved GFIl binding sites.
The sequence around the transcription start site of the rat Oftllocus was
compared to the sequences of the mouse and human Oftlloci. This analysis revealed a
great deal of homology among rat, mouse and human sequences up to 808 bp upstream of
the putative Inr of the rat locus (Figure 18A, gray areas). This amount of sequence
homology is unusual for non-coding DNA, emphasizing the probable importance of this
region in the transcriptional control of Oftl.
The Inr sequence is conserved in the mouse locus, but not in the human sequences
we identify here. However, the homologous region we show is defined as intron 1 of the
human gene (71). Human Oftl is reported to have more than one transcription start site,
and the major start site of the human Oftl promoter (72) contains a consensus Inr element
by our analysis (data not shown).
Since Oftl is repressed in GFIl and GFIlB transgenic thymocytes, we next
examined the sequence for GFIl/GFIlB binding sites by using a matrix similarity
program (73). Putative GFIl/GFIlB binding sites that are conserved among all three
species are annotated and underlined, as is the rodent Inr (Figure 18A). Furthermore,
alignment of the first intron of the rat locus revealed extensive homology and two
additional potential GFIl/GFIlB binding sites that are also conserved in all three species
(data not shown).

GFIl and GFIlB repression is conserved in the rat Gfil promoter.
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Figure 18. The rat Gfil promoter is highly homologous to mouse and human loci,
and is sensitive to repression by GFIl and GFIlB. A. Sequence alignment of mouse
and human Gfilloci to the rat Gfil promoter. Regions in gray represent areas of identity
among all three species. GFIl binding sites and the lnr are underlined and annotated.
Numbering is according to the rat sequence with +1 as the first nucleotide in the putative
lnr. B. The Gfil-promoter CAT reporter was cotransfected into 293T cells with CMV5
expression vector, or CMV5 expression plasmids encoding GFIl, GFIlB, or the
repression-mutant P2A-GFIl. Transfection efficiency was controlled by cotransfection
of a B-galactosidase expression construct. Relative CAT activity was derived by
normalization to B-galactosidase levels within individual transfections. The plot
represents the averaged normalized CAT activity ± SEM from triplicate transfections.
Similar results were obtained in three independent experiments. C. The VPI6-Zn
mutant encodes the transcriptional activation domain ofVP16 fused to the DNA-binding
Zn fingers ofGFIlB. VPI6-Zn activates transcription ofGFIl/GFIlB target genes (10).
The Gfil-promoter CAT reporter was cotransfected with CMV5 expression vector, or
CMV5 expression plasmids encoding VPI6-Zn. Normalization was performed as in A.
Fold activation was derived by dividing the normalized CAT activity in the presence of
VPI6-Zn to CMV5 vector controls.
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We next created a rat Gfi-promoter-reporter construct containing the sequence
from -808 bp 5' of the transcription start site to exon 2. This sequence contains all of the
DNase hypersensitive sites identified in the promoter region and first intron. Moreover,
this region is highly conserved between mouse, rat and human Gfilloci. Transfection of
several truncations of this construct into two different GFIl expressing cell lines resulted
in significant increases in reporter activity upon removal of the region between -808 and 245 (data not shown). Therefore, a negative regulatory element is present in the GFIl
promoter.
293T cells are transformed kidney epithelial cells that express a low level of GFIl
(data not shown), and were used for transient transcription assays. As shown in Figure
18B, co-transfection ofa Gfil promoter-driven CAT reporter construct and CMV5
expression constructs encoding GFIl or GFIlB resulted in decreased reporter activity in
comparison to empty CMV5 vector (P = 0.006, and P = 0.002 respectively). However,
co-transfection of the repression-defective P2A-GFIl has no effect on reporter activity
(Figure 18B). While these data provide the expected result that GFIl and GFIlB can
repress the Gfil promoter and that the repression observed is mediated by the SNAG
domain, they do not recapitulate the potent de-repression of the Gfil promoter as seen in
P2A-GFIl transgenic thymocytes. We consider that 293T cells may not express enough
endogenous GFIl to effectively repress multiple copies of the transfected reporter
construct, and that transient transcription assays do not reproduce all aspects of
chromatin-regulated gene expression.
To examine whether the repression of the rat Gfil promoter is due to direct
binding of GFIl to the promoter region, we utilized an expression construct encoding the
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activation domain of the herpes simplex virus VP16 protein fused to the zinc fingers of
GFIlB (VPI6-Zn) (10). This construct encodes a transcriptional activator with the DNAbinding specificity ofGFIl/GFIlB. Co-transfection of the GjiJ-CAT reporter with the
VPI6-Zn expression vector resulted in a dose-dependent increase in CAT activity (Figure
18C), suggesting that the observed repression by GFIl and GFIlB is a result of direct
binding ofthe promoter by GFIl and GFIlB. The high frequency of conserved putative
GFIl/GFIlB binding sites, along with the observed GFIl- and GFIlB-mediated
repression of both endogenous GjiJ in transgenic mice and rat GjiJ promoter-reporter
constructs, indicate that GjiJ is a direct target ofGFIl and GFIlB transcriptional
repression in mice and rats.

Human Gfil is repressed upon forced expression of GFIl or GFIlB.
To determine ifhuman GjiJ is also responsive to GFIl and/or GFIlB, we
transfected a human T cell line, lurkat, with a selectable marker and the Lck-CD2-GFIl
and -GFIlB constructs and selected stable clones. Western blot analysis revealed varying
expression levels ofGFIlB (Figure 19A, clones IB.l and IB.2), and high levels ofGFIl
(Figure 19B, clones 1.1 and 1.2). Northern blot analysis of poly-A+ selected RNA
(Figure 19C) with a human GjiJ-specific probe revealed that forced expression ofGFIl
or GFIlB resulted in repression of endogenous human GjiJ in lurkat T cells.
Furthermore, the repression by GFIIB is dose-dependent in that the clone expressing
higher levels ofGFIlB has lower steady state levels of GjiJ RNA (compare Figure 19A
and Figure 19C, clone 1B.l versus 1B.2). In contrast to the mild repression of GjiJ in
low-level-expressing GFIl transgenic mice (Figure 16B), high levels of GFIl result in a
dramatic decrease in steady state levels of GjiJ mRNA in lurkat T cells (compare Figure
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Figure 19. GFIl and GFIlB repress endogenous human Gfil in the Jurkat T-ALL
cell line. A and B. Western blot analysis ofGFIlB (A, IB.1 and IB.2) and GFIl (B, 1.1
and 1.2) in independent stably transfected and selected Jurkat clones. Blots in A and B
were probed with the same antisera as in Figure 16. C. Northern blot analysis of polyA+ RNA (5 ug) from Jurkat clones using a probe specific for human Gfil. Ethidium
bromide staining of the poly-A+ RNA is shown for equal loading. Similar results were
obtained with other clones.
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19B and Figure 19C, clones 1.1 and 1.2). Therefore the regulation of GjiJ by GFIl and
GFIl B is conserved among mice, rats and humans.

Jurkat nuclear extract can form in vitro proteinlDNA complexes with putative GFIl
binding sites in the rat Gfil promoter and intron.
The GFIl consensus binding site has been defined by in vitro studies as
TAAATCAC(AlT)GCA, with an absolute requirement for the AATC core (10;15). To
determine which of the putative sites in the GjiJ promoter bind to endogenous GFIl, we
designed 30-bp oligonucleotide probes for use in electrophoretic mobility shift assay
(EMSA) with Jurkat nuclear extracts. We observed several different proteinIDNA
complexes, some of which were unique to individual probes, and most of which were
relatively minor in intensity. However, one of the probes (GRP2), corresponding to a
putative GFIl binding site at -705 (rat AATC core relative to Inr), was strongly shifted in
a doublet with greatly retarded mobility (Figure 20). Another probe (GRP4), containing
two putative binding sites located at -434 and -421, shifted with the same pattern, but at a
much lower intensity. In order to begin to discern whether any observed binding may
suggest functionality, we engineered a probe to contain a GFIl binding site that has been
shown to be active in transient transcription assays (B30GRP; (9)). This probe contained
the B30 binding site and flanking sequence from a putative binding site located at -558 in
the rat promoter, and was named B30GRP. This probe shifted in the same doublet
pattern as did GRP2 and GRP4; however, the intensity of the shifted band was
significantly less than that observed for either endogenous promoter sequence. Complex
formation was competed away by adding excess cold oligonucleotide (Figure 20).
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Figure 20. Formation of protein-DNA complexes with Jurkat nuclear extract and
oligouncleotide probes containing GFIl consensus binding sites in rat Gfil promoter
sequence. A. Of seven oligonucleotide probes containing a total of eight predicted GFIl
recognition sites (GRP4 has two sites) in the rat Gfil proximal promoter, only GRP2 (705) and GRP4 (-434 and -421) display appreciable binding to proteins in Jurkat nuclear
extract. Migration of the complexes formed with these two probes is identical to the
migration of complexes formed between Jurkat nuclear extract and a synthetic consensus
GFIl binding site (B30GRP). Note: These data were generated by Morgan Jeffries
under the direction of Loretta Doan. B. A probe containing two putative GFIl binding
sites located in the intron of the rat and mouse genes (GRI) also forms these complexes
when incubated with Jurkat nuclear extract.

C. The sequence of the rat promoter with

the locations of the probes indicated. Each probe sequence is underlined, and the AATC
core of each putative GFIl binding site is in bold. The italicized nucleotide is contained
in both GRP1 and GRP2. The INR is also indicated in bold.
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Further examination of potential regulatory elements in the rat intron revealed two
putative GFIl binding sites that are conserved in the mouse intron (data not shown).
These sites lie close together and are both contained in the probe GR!. Figure 20 shows
that this probe shifts in a doublet pattern identical to that observed with the promoterbased probes, and that this binding can be competed by the addition of excess cold probe.

GFIl binds directly to a predicted GFIl binding site in the rat Gfil promoter.
To determine whether GFIl is present in, and required for, the complexes
observed in the doublet, we more closely examined the properties of complexes formed
between Jurkat nuclear extract and GRP2. Pre-incubation of Jurkat nuclear extract with
antiserum against GFIl disrupted the complexes (Figure 21A); no effect was noted using
a control antiserum. Additionally, as observed in Figure 20, complex formation was
efficiently competed in the presence of excess cold wild-type probe, but not in the
presence of excess cold mutant probe (AATC->GGTC). Finally, when the mutant probe
was labeled and incubated with Jurkat nuclear extract, the doublet was not detected.
Combined, these EMSA results demonstrate that complex formation on the -705
oligonucleotide requires both GFIl and the Ofi] recognition sequence, strongly
suggesting that GFIl is binding directly to this site. Similar results were obtained with
other potential binding sites for GFIl (data not shown).
To ensure that GFIl and GFIlB are capable of binding to the -705 site, we
performed EMSA with in vitro transcribed and translated (IVT) proteins. As published
by others (14), we note that IVT mouse GFIlB results in two proteins (Figure 2IB). IVT
GFIl and GFIlB shifted the -705 oligonucleotide in EMSA (Figure 2IC), and two
protein-DNA complexes are seen in the presence of the two GFIlB products. GFIl
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Figure 21. GFIl and GFIlB bind in vitro to a conserved site in the rat Gfil
promoter. A. EMSA analysis of GFIl binding to the conserved site at -705 bp. Jurkat
nuclear extract incubated with the -705 bp probe alone (lane 2) forms several distinct
protein-DNA complexes. Supershift analysis was performed with a goat polyclonal
antibody to GFIl (lane 3). Pre-immune goat sera served as control (lane 4). Cold
competition was performed with a 30-fold excess of cold probe (lane 5), or cold mutant
probe (AATC to GGTC) (lane 6). Incubation of Jurkat nuclear extract with a labeled
mutant probe (lane 6). W = wild type probe, M = mutant probe, G = goat anti-GFIl
antiserum, Cg = control goat antiserum. B. In vitro transcribed and translated GFIl,
GFIlB, or a mutant ofGFIllacking the fourth zinc finger (~Zn4) were 35S labeled, run
on a denaturing polyacrylamide gel, and subjected to autoradiography. Representative
autoradiographs are shown. C. IVT GFII and GFIlB, but not ~Zn4 GFIl, form
complexes with the -705 oligonucleotide probe. Note: These data were generated by
Morgan Jeffries under the direction of Loretta Doan.
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requires zinc fingers 3, 4, and 5 for sequence-specific DNA binding (15). As expected,
EMSA using a mutant of GFIl lacking zinc finger 4

(~n4;

Figure 21 C) did not result in

retarded mobility ofGRP2. These data support the suggestion that GFIl in Jurkat
nuclear extract is binding directly to these identified sites. Furthermore, the relatively
faster mobility of the complex formed between DNA and IVT GFIl, as compared to the
mobilities of the two bands in the doublet observed with Jurkat nuclear extract, suggests
that in nuclear extract, GFIl exists in complexes with other proteins.
Potential differences in DNA sequence requirements for binding by GFIl in nuclear
complexes.

The GFIl consensus site was defined by using synthetic oligonucleotides and
bacterially synthesized proteins encoding GST fused to GFIl (15). This sequence is
utilized by the matrix homology program MatInspector (73) to identify putative GFIl
binding sites in the promoters of user-defined genes. When MatInspector identifies
putative recognition sequences, it also assigns a percent consensus score to the sites in
question. We limited our analyses to sites that had a 90% or greater score. We expected
those sites with the highest scores to show the most efficient binding to GFIl. However,
the relative binding differences we observed in our EMSA analysis using Jurkat nuclear
extract as a source for GFIl did not agree with the predicted affinities. Due to the limited
number of oligonucleotide probes (eight), our initial examination failed to identify a
common sequence requirement among those that bound GFIl when compared to those
that did not. However, upon further examination of the promoter sequence, and
comparison to the public domain sequences that became available during the course of
this work, we discovered seemingly minor discrepancies in the sequences of both GRP2
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and GRP4. (The other sequences used in probes of putative binding sites were verified as
accurate by the same analyses.) Specifically, the apparently correct sequence of GRP2
has an A at the position +6 from the first A of the AATC core (instead of the T in our
original probe), while GRP4 contains a T at position -2 (instead of the C in our original
probe) (Figure 22A). We predicted that neither change in sequence would alter binding
by GFIl because, in the in vitro experiments that first defined the GFIl consensus
sequence, both nucleotides were selected in approximately the same number of
oligonucleotides in each case (15). To test this prediction, we re-synthesized the
oligonucleotide probes with the correct sequence and performed EMSA to compare GFIl
binding.
As seen in Figure 22B, the T to A change in the sequence of GRP2 affected
neither the pattern nor the intensity of complex formation (compare GRP2 and GRP2.2).
However, the C to T alteration of the first site in GRP4 drastically changed the pattern of
complex formation (compare GRP4 and GRP4.2). GRP4.2 shifts in a single complex
with a somewhat faster mobility than the lower band in the doublet observed with GRP2,
GRP2.2, and GRP4. Competition assays defined this first site as being solely responsible
for the observed GFIl binding in both GRP4 probes (data not shown). This suggests that
there are several GFIl-containing complexes in lurkat nuclear extract, and that changing
the nucleotide at -2 from C to T alters the ability of these complexes to bind. Similar
results were obtained when nuclear extract from Nb2 cells were used as the source of
GFIl (data not shown). While suggestive, these data are certainly not conclusive, and
this hypothesis remains to be tested.

102

Figure 22. Jurkat T cell nuclear extracts contain multiple GFIl complexes with
specific DNA sequence requirements and varying DNA binding affinities. A.
Sequence alignment of oligonucleotide probes. The sequences of the original probes are
indicated as GRP2, GRP4, GRI, and B30GRP. Probe GRP2 contains the site at -705, and
probe GRP4 contains two binding sites at positions -434 and -421. Probe B30GRP is a
consensus GFIl binding site with flanking sequence from the Gfil rat promoter that
surrounds a putative binding site at -558. The ultimately resolved sequences of the rat
promoter are indicated as GRP2.2 and GRP4.2. The changed nucleotides are shown in
bold. B. GRP2, GRP2.2, and GRP4 show the same binding pattern, but GRP4.2 forms a
single complex with greater mobility than either of those formed with the other three
probes. C. Cross-competition confirms the relative binding affinities of oligonucleotide
probes (Figure 20). GRP2.2 was radiolabeled and used as probe (lane 1, probe only; lane
2, probe with 1urkat nuclear extract). Competition analysis was performed using
increasing molar amounts (1 OX, 25X, and 50X the ng quantity of probe) of GRP2.2
(lanes 3-5), GRP4.2 (lanes 6-8), GRI (lanes 9-11), mutlGRI (the first AATC mutated to
GGTC; lanes 12-14), mut2GRI (the second AATC mutated to GGTC; lanes 15-17), and
mut3GRI (both AATC mutated to GGTC; lanes 18-20). GRP2.2, GRI, and mut2GRI all
compete with GRP2.2 for binding to GFIl in 1urkat nuclear extract. GRP4.2, mutl GRI,
and mut3GRI do not compete. (NE = 1urkat nuclear extract.)
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To ensure that the observed differences in intensities of the complexes are a result
of the relative strength of binding by GFIl and not due to artifact such as poor probe
labeling, we performed cross-competition analysis (Figure 22C). In this assay, GRP2.2
was used as radio labeled probe, and competition was performed using different unlabeled
oligonucleotides. This analysis showed that the corrected site at -421 (GRP4.2) does not
compete away the binding to the site at -705 (GRP2.2). Furthermore, it confirmed that
the affinity for GFIl binding to GRP2 is greater than that for binding to the intronic sites
(GRI), as GRI does not effectively compete for binding unless added in 25 or 50 fold
excess, whereas GRP2.2 completely competes its own binding at 10 fold excess. The
reverse experiment was also done, in which GRP2.2 effectively competes all binding by
GRI when added in 10 fold excess (data not shown). In addition, analysis of the AATC
to GGTC mutants of each of the putative binding sites in GRI reveals that the first site is
solely responsible for competition; when this site is mutated, GRI is unable to compete
with GRP2 even at 50 fold excess (compare lanes 9-11 and 12-14). However, mutation
of the other intronic site did not affect competition (compare lanes 9-11 and 15-17).
Therefore, the first of the two predicted GFIl binding sites in the intron is bound by
GFIl, whereas the second is not. Furthermore, the site at -705 binds more GFIl complex
than does any other GFIl binding site identified in our in silico analyses.

GFIl autoregulation is not observed in a myeloid lineage cell line.
Both Gjirl - mice and Gjil-mutant humans display profound neutropenia
(12; 16; 17), indicating a role for GFI1 in myeloid differentiation. U937 is a bi-potential
human myeloid-precursor cell line that can differentiate into monocytes or neutrophils
(74). U937 cells express GFIl (13). To determine if GjiJ autoregulation is active in non-
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Figure 23. GFIl autoregulation occurs in T cells but not in a myeloid-lineage cell
line. A. Western blot analysis of human U937 cells transduced with retroviruses
encoding Flag-tagged GFIl with an anti-Flag antibody (top) or anti-GFIl antibody
(bottom). Note: These data were generated by Dr. Christopher M. Jay. B. Northern blot
analysis of endogenous Gfil transcripts using a probe specific to the human Gfil 3'
untranslated region. C - F. Chromatin immunoprecipitation analysis of wild type Jurkat
T cells or U937 cells using either rabbit or goat polyclonal antisera to GFIl (aGFIl Ab).
Non-specific rabbit and goat sera served as control (control Ab). Primers for the
amplification reactions targeted the promoter or 3' untranslated region of human Gfil.
Input = 0.005 to 0.01 % of input chromatin. J = Jurkat. U = U937. P = promoter. 3' = 3'
region of Gfil. R = rabbit polyclonal antiserum G = goat polyclonal antiserum. Note:
These data were generated by Zijun Duan and Marshall Horwitz (Department of
Medicine, Division of Medical Genetics, University of Washington School of Medicine).
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lymphoid lineages we transduced U937 cells with retroviral vectors encoding Flagepitope-tagged GFIl (Figure 23A, U1.1 and U1.2). This Flag-tagged GFIl was
confirmed to be an active transcriptional repressor in transient transcription assays (data
not shown). The transduced U937 cells express the epitope-tagged GFIl and have higher
levels of GFIl overall (Figure 23A); in fact, the level of expression was similar to that
observed in the stably transfected Jurkat T cells (compare Figure 19B with Figure 23A).
However, we did not observe profound repression of the endogenous Gfillocus in U937
cells (Figure 23B). While there appears to be a mild reduction in the expression of
endogenous Gfil, it does not compare with the repression observed in Jurkat T cells. We
therefore conclude that, unlike T lymphocytes, U937 myeloid cells do not display
effective Gfil autoregulation.

GFIl binds the Gft] promoter in live T cells.
To determine the biological relevance of Gfil autoregulation, we performed
chromatin immunoprecipitation (ChiP) analysis of cross-linked protein-DNA complexes
from Jurkat T cells. This technique reveals protein-DNA interactions within the context
of living cells. Amplification using primers that flank the -705 GFIl binding site resulted
in a PCR product from chromatin immunoprecipitated with rabbit antisera to GFIl, but
not when immunoprecipitation was performed using control antisera (Figure 23C).
Essentially the same result was found with goat antisera to GFIl and control goat antisera
(Figure 23D). In contrast, using the same analysis, we were unable to amplify a product
using primers to a 3' region of Gfil (that does not contain GFIl binding sites by our
analyses) (Figure 23E). Thus, the ChiP result is specific to the promoter region of Gfil.
While the ChiP analysis does not prove that GFIl is specifically bound to the -705 site,
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these in vivo data show that GFIl does bind its own promoter in living T cells.
Moreover, these data suggest that the Gfil autoregulation we observe is indeed a
physiologically relevant cellular mechanism.

GFIl does not bind the Gfil promoter in living myeloid cells.
We repeated ChIP analysis with the U937 cell line. In contrast to our results with
lurkat cells, we did not find GFIl bound to the Gfil promoter in U937 cells (Figure 23F).
These data provide a potential reason for the lack of repression observed in Figure 23B.
GFIl in U937 cells is capable of DNA binding, as we have published the binding ofGFIl
to a number of promoters in this cell line (13). Furthermore, the general chromatin
environment of the Gfillocus is permissive for DNA binding, as U937 cells express
endogenous GFIl (Figure 23A). It is of course possible that localized chromatin control
may alter the promoter to make the GFIl binding sites inaccessible. In any case, the
ChIP analyses indicate that GFIl autoregulation is not active in all cells that express Gfil,
and may not occur in cells of myeloid lineage.

Discussion
GFIl is a transcriptional repressor protein that plays important biological roles in
hematopoietic and neuronal cell development (11;16;17;75). Gfil was originally
identified in an in vitro screen for genes that, upon deregulated expression, engender
progression of T cell leukemias to Interleukin-2 independent growth (8). Transgenic
overexpression of GFIl is poorly oncogenic, but potently collaborates with transgenic
expression ofMYC or PIM oncoproteins to cause leukemia (76). In contrast, deletion of

Gfilleads to profound lymphopenia (16;17). Since Gfil expression is critical for normal
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hematopoiesis, and overcoming regulatory control of GjiJ accelerates oncogenesis, the
transcriptional control of GjiJ is of great interest. Here we have shown that GFIl, and
the closely related GFIlB, both repress the transcription of mouse, rat, and human GjiJ.
We present several lines of evidence supporting a direct and physiologically
relevant mechanism of GjiJ repression by GFIl. First, GFIl binding sites in the rat GjiJ
promoter are conserved in the mouse and human GjiJ loci. Second, in primary
thymocytes, transgenic expression of GFIl correlates with repression of endogenous
GjiJ steady-state mRNA levels, whereas expression of a repression-defective GFIl

mutant correlates with a profound de-repression of murine GjiJ. Third, in the human
lurkat T cell line, forced overexpression of GFIl correlates with reduced endogenous
GjiJ steady-state mRNA levels. Fourth, in EMSA analysis, in vitro transcribed/translated

GFIl and endogenous GFIl-containing nuclear complexes bind sequences in the rat GjiJ
promoter. Finally, ChIP analyses with two different antisera indicate that GFIl binds to
its own promoter in living lurkat T cells. These in vitro and in vivo analyses provide
strong support for the hypothesis that GFIl regulation of GjiJ is physiologically relevant.
In fact, GjiJ autoregulation is evolutionarily conserved, as pag-3, the Caenorhabditis
elegans ortholog of GjiJ, is autoregulated (77).
GFIl and GFIlB control GjiJ expression. The abilities of GFIl and GFIlB to
repress endogenous GjiJ seem comparable. Similar expression levels of the two factors
in stably transfected lurkat T cells resulted in similar repression. Furthermore, cotransfection of equal amounts ofGFIl and GFIlB expression plasmids with a GjiJ
promoter-driven reporter resulted in nearly equal levels of repression. The regulation of
Gjil by GFIlB is reciprocated. In addition to the data presented here, ChIP analysis in
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KG-I, U937, and lurkat cells using antibodies against GFIl demonstrated that GFIl
binds to the GfilB promoter region in living cells (13). Together, these data suggest
cross-regulation of Gfil and GfilB.

GFIl/GFIlB cross-regulation provides a potential explanation for differential
steady-state expression of Gfil and GfilB, and suggests a molecular mechanism to ensure
that the function of the properly expressed transcription factor is not blocked by aberrant
expression of the other. We note that both factors can be simultaneously expressed (19).
Specifically, Gfil and GfilB are co-expressed during specific stages ofT cell
development coincident with activation (19). The repression of Gfil by GFIlB provides
new insight into the transient expression of GFI 1B in thymocytes that have been recently
signaled for positive selection. Namely, GFIlB may be present to temporarily repress

Gfil, thereby decreasing the potentiative effect of GFIl on TCR stimulation and finetuning the cellular response to activation. Since GFIl increases T cell activation (19-21),
GFIlB expression may indirectly inhibit T cell activation through the repression of Gfil.
Mutation of GFIl in both mice and humans causes profound neutropenia
(12;16;17). Since the primary function ofneutrophils is to defend against bacteria and
fungal infection (78), humans with either Severe Congenital Neutropenia (SCN) or
"nonimmune chronic idiopathic neutropenia of adults" (NI-CINA) are predisposed to
opportunistic infections (79). We have recently shown that GFIl is mutated in SCN and
NI-CINA patients without mutations in neutrophil elastase (ELA2) (12), the most
prevalent mutation in SCN (79). In contrast to ELA2-mutant SCN patients, GFIl-mutant
SCN patients are also mildly lymphopenic and have T cell activation defects (12).

In

mice, deletion of Gfil results in a profound neutropenia that is strikingly similar to that
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seen in human GFIl-mutant SCN patients (16). However, the lymphoid phenotype of

Gjirl - mice is dramatically worse than that ofGFIl-mutant SCN humans (16;17;17).
Cell type specific Gjil autoregulation may explain the disparity between the
lymphoid phenotype of Gjirl - mice and Gjil-mutant humans. Our T-cell specific P2AGFIl transgenic mice lack a Gjil-deleted phenotype and demonstrate significant derepression of the endogenous Gjil locus. Thus, by interfering with the transcriptional
repression activity of endogenous GFIl, the P2A-GFIl mutant may induce compensation
in T cells to prevent a complete loss of GFIl function. In fact, humans with SCN are
heterozygous for mutant Gjil (12). In a manner similar to the P2A-GFIl transgenic
mice, the expression of the mutant GFIl in SCN patient T cells might lead to derepression of the wild-type allele, providing compensatory expression of wild-type GFIl
and sufficient GFIl activity in these cells. In contrast, myeloid progenitor cells, like the
U937 myeloid lineage cell line, may not exhibit Gjil autoregulation. These cells would
not have compensation by the wild-type allele and would effectively lose most or all
GFIl function. Thus, cell-type specific Gjil autoregulation provides a potential
explanation for the differences in phenotype observed in Gjirl - mice when compared to
humans with a mutation in a single allele of Gjil.
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CHAPTER V
GFIlB INTERFERES WITH POSITIVE SELECTION OF TCR TRANSGENIC
THYMOCYTES

Introduction.

A central tenet ofT cell-mediated immunological functions is the requirement for
recognition of haplotype-specific MHC molecules by the TCR. Indeed, it is the
combination of antigen and the haplotype of the presenting MHC molecule that
determines the response or nonresponse of a mature T cell. The induction of an immune
response requires that the TCR recognize foreign antigen in the context of self-MHC. On
the other hand, the presentation of self antigen by self-MHC results in low-level TCR
signaling and survival, but not activation, of T cells. This principle also governs the
positive selection of thymocytes. Thymic antigen presenting cells present a wide variety
of self antigen in the context of self-haplotype specific MHC molecules. In fact, it is
thought that thymic APC have access to virtually all potential self-antigens, thereby
providing to developing T cells the potential to interact with these self antigens. These
interactions ensure both the development of a very diverse T cell repertoire and the clonal
deletion of all potentially self-reactive T cells (recently reviewed in (80)). Furthermore,
under normal physiological circumstances, thymocytes are restricted and selected by selfMHC only, ensuring the recognition of foreign MHC as foreign. Therefore, the MHC
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haplotype that can successfully select a T cell bearing a specific TCR is fixed and can be
experimentally determined.
This central principle has been exploited by researchers to generate tools that
further enhance our understanding of TCR-MHC interactions. TCR transgenic mice have
been generated in which T cells predominantly express only the engineered transgenic
TCR. Both the MHC specificity and the antigenic specificity of these transgenic TCRs
are known, allowing researchers to more closely examine TCR-antigen-MHC interaction
as well as specific processes of T lymphopoiesis that are governed by these interactions,
such as positive and negative selection. We have used these systems to further
investigate the phenotype of our GFIlB transgenic mice.
Our initial phenotypic analysis of GFIlB transgenic thymi presented results that
were unexpected in the context of accepted theories of thymocyte selection and
maturation. Specifically, we found that GFIlB transgenic thymocytes and T cells are
defective in TCR signaling (Chapter 2). Currently accepted theory ofT lymphopoiesis
suggests that a stronger or more persistent TCR signal is required for the formation of
CD4 SP cells and that a weaker or less persistent signal results in the formation of CD8
SP cells (recently reviewed in (81;82)). According to this theory, GFIlB transgenic mice
should generate more CD8s and fewer CD4s when compared to wild type mice.
Contrary to this, we discovered that GFIlB transgenic mice have an unusually high
percentage and number of CD4 SP cells (Figure 10, chapter 2). Furthermore, these CD4
SP cells are phenotypically mature as determined by low expression of the maturation
marker CD24IHSA. Given the down-modulation ofTCR signals observed in GFIlBtransgenic T cells, we reasoned that the abnormal CD4 SP cells in GFIlB transgenic mice
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may be the result of aberrant positive selection ofDP thymocytes that should have
received a stronger signal and, therefore, should have been deleted.
Preliminary studies examining negative selection indicated little or no effect of
the GFIlB transgene. These studies include flow cytometric apoptosis assays of
thymocytes, examination of deletion of specific V~ subsets in thymocyte populations,
and expansion and survival ofV~ subsets in the periphery (data not shown). Because no
difference was observed between GFIlB transgenic mice and wild type littermate
controls in these experiments, we did not further investigate negative selection as a
mechanistic explanation for the GFIlB transgenic phenotype. Rather, we decided to
pursue positive selection as the mechanism.
To determine whether GFIlB affects positive selection, we crossed GFIlB
transgenic mice with mice that express a transgenic TCR. All mice were crossed onto a
Rag2-1- background so that no rearrangement of endogenous TCR loci would occur. In
addition, to reduce the possibility of TCR transgene-specific effects, we used two
different TCR transgenic lines, AND and DO.II. Both TCR transgenes are MHC Class
II restricted and, when on a genetic background expressing the proper selecting MHC
molecules, result in the positive selection of large numbers of CD4 SP cells (83-86).
We discovered that in these systems, transgenic expression of GFIl B results in a
reduction in the number of CD4 SP cells, with a concomitant increase in the number of
DP thymocytes. Furthermore, a large percentage of those CD4 SP cells that are
generated are phenotypically abnormal, displaying properties of both mature and
immature SP thymocytes. In addition, micro array analysis provides insight into changes
in the transcription levels of genes that are known to contribute to T cell activation, and
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EMSA analysis provides preliminary evidence that these TCR signaling pathways are
affected in GFIIB transgenic thymocytes.

Materials and methods.
Mice. Rag-I - TCR transgenic mice were obtained from Taconic Farms. These mice have
bred true for generations and therefore transmit one copy of the trans gene to all progeny.
Rag-I- GFIlB transgenic mice were generated by crossing Rag-I - mice (Taconic Farms)

with GFIlB transgenics, all on a B6 background. GFIlB transgenic, Rag+l - progeny were
backcrossed to Rag-I- mice to generate Rag-I- GFIlB transgenic mice. These were mated
with Rag-I - TCR transgenics to generate litters of Rag-I- TCR transgene+ and GFIlB+ or
GFIlB- animals for experiments.
Flow cytometry and antibodies. Flow cytometric methods have been described in
Chapter 3. Antibodies used include CD4 (RM4-5 and GK1.5) and CD8a (53-6.7),
CD24a-(M1I69), CD69 (H1.2F3), and CD62L (MEL-14), all from BD Pharmingen.
RNA isolation and microarray. For microarray analysis, single cell suspensions of
thymocytes were prepared. Phenotypes of mice were confirmed by flow cytometric
analysis, and RNA was extracted from thymocytes with UltraSpec RNA Isolation System
(Biotecx) following the manufacturer's protocol. Microarray analysis was performed in
the Brown Cancer Center Microarray core facility of the University of Louisville.
EM SA. Electrophoretic mobility shift assays were performed according to the protocol
described in chapter 2 with the following modifications. Probes were oligonucleotides
from Santa Cruz Biotechnology (sc-2501, sc-2505, and sc-2525) and were labeled with
Polynucleotide Kinase (New England Biolabs) following a standard protocol. 2.5
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nuclear extract was incubated with 1 uL of radio labeled oligonucleotide probe (100,000
cpm). Complexes were electrophoresed through 6% polyacrylamide gels, dried, and
exposed to film.

Results and discussion.
Transgenic expression of GFIlB results in decreased positive selection and the
presence of abnormal MHC Class II restricted TCR transgenic thymocytes.
To determine the effect oftransgenic expression ofGFIlB on positive selection of
thymocytes, we crossed AND transgenic mice to GFIlB transgenic mice. The resulting
FI progeny are H_2b/d, which is a positively selecting background for AND TCR
transgenic thymocytes (83). When we examined the thymi of these progeny, we
observed a large percentage ofthymocytes were CD4 SP in the GFIlB- AND transgenic
mice, in accordance with previously published results. However, when transgenic GFIlB
is expressed, the percentage and number of CD4 SP thymocytes is decreased to
approximately half those of controls (Figure 24A). The total number ofthymocytes is
not different between GFIlB transgenics and GFIlB-littermate controls, and the
difference in the number of CD4 SP cells is inversely correlated with a difference in the
number ofDP cells. Similar results were obtained with DO.lI/GFIlB bi-transgenics
(Figure24B), though both the decrease in CD4 SP cells and the increase in DP cells in
GFIlB transgenics are even more pronounced in this case. DO.lI mice do not produce
the same large percentage ofCD4 SP cells observed in AND transgenics (86), and our FI
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Figure 24. Transgenic GFIlB decreases the number of CD4 SP cells in Class II
restricted TCR transgenic mice. A. Flow cytometric plot ofCD4 v CD8 of Rag-1AND TCR transgenic and Rag-I- AND TCR GFIlB bi-transgenic mice. DP and CD4 SP
populations are gated, and percentage of total cells indicated. The MHC haplotypes of
these FI mice are bid. The table below the graphs gives absolute numbers of cell
populations. B. The same analyses were applied to Rag-I - DO.II TCR transgenic mice
(MHC b/d).
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mice are of a mixed haplotype; d (positively selecting) and b (negatively selecting).
Therefore, we cannot rule out a role for negative selection in the disparity of CD4 SP in
DO.Il1GFIlB bi-transgenics, though preliminary data would suggest that GFIlB does
not affect negative selection (discussed above). Nonetheless, the results from both Class
II restricted transgenic TCR systems are consistent with an interference of positive
selection by transgenic GFIl B.
Because we had observed abnormal phenotypically mature CD4 SP cells in
GFIlB single transgenic mice (Chapter 2 and Figure 25), we examined the CD4 SP cells
in our bi-transgenic system for the expression of several maturation markers. As normal
thymocytes mature, they downregulate the expression of CD24 and CD69 (Figure 25).
However, GFIlB transgenic mice display an abnormal population ofCD4 SP thymocytes
that are CD69hi CD24lo (Figure 25). Additionally, normal thymocytes upregulate the
expression of CD62L as they mature (data not shown). When considered together, these
three markers can be used to track the maturation of thymocytes. The most mature
thymocytes are those that express low levels of CD24 and CD69 and high levels of
CD62L. These thymocytes are equivalent to immature T cells, and exit the thymus to
take up residence in peripheral lymphoid compartments (87).
CD62L is a homing molecule for mature T cells that directs them into the
peripheral lymphoid compartments (88). The activities of CD24 and CD69 have not been
firmly established in T lymphopoiesis; however, it has been suggested that CD69, a
glycoprotein, serves as an anatomical anchor, preventing the premature egress of
developing thymocytes (89;90). Therefore, in order to exit the thymus and home to
peripheral lymphoid compartments, a cell must both downregulate CD69 and upregulate
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Figure 25. GFIlB transgenic CD4 SP thymocytes display abnormal levels of
maturation markers. Shown are plots of CD4 SP cells from one wild type and one
GFIlB transgenic mouse. The GFIlB transgenics have an abnormal population of cells
expressing low levels ofCD24, most of which express high levels ofCD69. In addition,
GFIlB transgenics lack a substantial CD24int CD6910 population.
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CD62L. The increase in CD4 SP cells that we observed in our GFIl B transgenic mice
was comprised of cells that express low levels of CD24 (Figure 1DC), suggesting that
these cells were phenotypically mature. However, these cells also express high levels of
CD69 (data not shown), suggesting abnormal maturation. We therefore examined the
CD4 SP cells generated in our GFIlB/TCR bi-transgenic systems for maturity based on
CD24, CD69, and CD62L expression.
As shown in Figure 26, GFIlB- TCR transgenic CD4 SP cells are mostly CD24hi
CD69

hi

,

with a relatively abundant population expressing intermediate levels of both

markers, suggesting a normal maturation process. Furthermore, a good percentage of
these cells express CD62L, suggesting phenotypically mature thymocytes with the
capacity to exit the thymus and home to the periphery. In contrast, GFIlB+ TCR
transgenic CD4 SP cells are largely CD2410 CD69hi , suggesting abnormal maturation. In
addition, very few GFIlB transgenic CD4 SP cells express CD62L. Therefore, though
GFIlB transgenic mice generate CD4 SP cells with certain markers of mature
thymocytes, these cells may be unable to exit to the periphery and home to lymphoid
compartments due to continued expression of CD69 and a lack of expression of CD62L,
respectively.
Microarray analysis reveals alterations in expression of several genes involved in
TCR signaling pathways in GFIlB transgenic thymocytes.
We hypothesize that GFIlB interferes with TCR-induced signaling, resulting in a
decrease in the strength of signal that the cell interprets. Much is known about the
pathways involved in, and the ultimate downstream effectors of, TCR-induced signals.
Figure 27 is a simplified schematic representation of some of the major players in three
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Figure 26. CD4 SP cells ofTCR GFIlB bi-transgenic mice do not mature normally.
A. CD69 or CD62L v CD24 in CD4 SP thymocytes of Rag ,I, AND TCR transgenic or
GFIlB littermates. Percentages of gated populations are indicated. B. The same
analyses applied to Rag'I' DO.II TCR transgenic mice.
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Figure 27. Schematic representation of major effectors in TCR signaling pathways.
Modified from Singer and Koretzky, STKE website. The three major pathways depicted
result in the transcriptional activation of three different factors. Activation of both NFKB and AP-l requires signaling through the second messenger diacylglycerol (DAG).
However, the activation ofNF-KB is PKC-dependent whereas the activation of AP-l is
mediated through the Ras pathway. Activation ofN-FAT is mediated through the
calcium!calcineurin pathway.
http://stke.sciencemag.org/contentivolO/issue2003/images/datalCMP 70 19/DC 1IS inger4 2003.jpeg
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Figure 27
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distinct TCR signaling pathways. Each pathway activates a distinct downstream effector.
That is, calciumlcalcineurin-mediated signaling results in the activation of Nuclear Factor
of Activate T-cells (N-FAT), whereas PKC-dependent signaling results in an increase in
the transcriptional activation of Nuclear Factor kappa B (NFKB), and signaling through
the Ras pathway induces activation of AP-l, the Fos/Jun family of transcriptional
activators. As all of these are required for a full response to TCR activation, interference
with any of them would result in a decrease in that response. We therefore performed
micro array analysis on TCRIGFIlB bi-transgenic thymi and examined the expression of
known members of these pathways.
Figure 28 is a table of absolute signals from our microarray analysis. Included in
the table are genes involved in TCR signaling that we found to be different between
GFIlB+ and GFIlB- mice. We first examined the expression of Gfil, which we have
shown to be repressed by GFIlB, and of GfilB itself, as we would expect to see increased
levels of Gfil B transcript in GFIlB transgenic cells. Indeed, GFIlB transgenic
thymocytes express drastically reduced levels of Gfil message and increased levels of

GfilB transcript when compared to littermate controls (Figure 28). Furthermore, GFIlB
transgenics express increased levels of diacylglycerol kinase zeta (DGKt;), a negative
regulator of diacylglycerol (DAG) signaling. As depicted in Figure 27, this increase
alone may be sufficient to decrease the activation of both NFKB and AP-l upon induction
ofTCR signals. Additionally, GFIlB transgenics express decreased levels of both PKC8
and RasGRP2, further contributing to the block in activation ofNFKB and AP-l,
respectively. These results must be confirmed by either Northern blot analysis or RT-

peR. However, in order to justify further investigation into this potential mechanism, we
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Figure 28. GFIlB transgenic thymocytes display abnormal expression of
transcripts relevant to TCR signaling pathways. Signals of Affymetrix MOE430
microarray of RNA in thymocytes from two GFIlB/AND bi-transgenic and two GFIlBAND TCR transgenic littermate controls. In GFIlB transgenic animals, Gfil transcript is
reduced, and GfilB transcript is increased, when compared to GFIlB-littermate controls.
The array has two different probe sets to examine DGK(; both are listed. Though
absolute values for GFIlB transgenic animals are not always higher than controls, the
trend is that GFIlB transgenic thymocytes have increased levels of DGK(message. The
signal for PKC() is lower in the single probe set for that gene, and all three probe sets for

RasGRP2 show decreased levels of this transcript in the GFIlB transgenics. Signal
values were normalized using global scaling to a constant factor to compensate for
variation in sample processing.
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needed preliminary evidence that the downstream effectors of these signaling pathways
are also affected in the GFIlB transgenics.

EMSA analysis suggests that NFKB and AP-l are less active in GFIlB transgenic
thymocytes.
NFKB and AP-I are activated in response to TCR signals, and this activation is
often measured by examination of DNA-binding capacity of these factors in nuclear
extracts. We therefore performed EMSA analysis to compare the activity of these
transcription factors in GFIlB transgenic thymocytes and GFIlB negative littermate
controls. As a control for equal nuclear extract loading, we included probes for CIEBP,
which is not responsive to TCR activation. Figure 29 shows the results of this analysis
for both AND and DO.II TCR transgenics. In AND TCR transgenics, expression of
transgenic GFIlB results in a decrease in DNA binding by both NFKB and AP-I, but
does not affect DNA binding by CIEBP (Panel A). These results are consistent with the
gene array data in which we observed increased expression of Dgk( and decreased
expression of both PKC8 and RasGRP2e (Figure 28). Examination of the DNA binding
activity of these same transcription factors from DO.lI GFIlB transgenic thymocytes
revealed decreased activity ofNFKB, but not of AP-I or CIEBP. These preliminary
results, while far from conclusive, provide biological impetus to continue exploring the
effects ofGFIlB on both PKC- and Ras-mediated TCR signaling.
Future experiments to determine whether these pathways are affected in the
GFIlB-mediated block to positive selection include Northern blot or RT-PCR analysis as
previously mentioned. In addition, promoter and ChiP analyses would help to determine
whether the decreased expression of PKC8 and RasGRP2 are the result of direct
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Figure 29. Transgenic GFIlB decreases DNA binding by TCR downstream
effectors in bulk thymocytes. A. EMS A analysis of DNA binding by NFrl3, AP-I, and
CIEBP in thymocyte nuclear extract from Rag-I - AND TCR GFIlB bi-transgenic and
littermate controls. Transgenic GFIlB results in decreased intensities of shifts for both
NFrl3 and AP-I, but not for C/EBP. B. The same analyses applied to nuclear extract
from a different transgenic TCR (Rag-I-DO .11 TCR transgenic mice) reveals decreased
binding by NFrl3, but not by AP-I or CIEBP.
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repression by GFIlB. Expanding on the results obtained by EMSA, the same analyses
should be repeated on sorted DP TCRhi thymocytes (the stage at which positive selection
occurs and endogenous GfilB is expressed) to detennine whether in this population, the
activities ofNFKB and AP-l are truly decreased. Additionally, TCR transgenic
thymocytes could be activated and the same analyses perfonned to further support the
theory that this is a TCR-mediated inducible effect. In sum, the data presented here are
preliminary and provide a solid framework and good starting point for future work
investigating the mechanisms by which GFIlB decreases positive selection.
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CHAPTER VI
CLOSING REMARKS

The T lymphopoietic process is of great interest for many reasons. Not only has
the study of this developmental pathway led to a greater understanding of immunity and
autoimmunity, but it is also a good model for studying developmental processes in
general. While most development ceases after embryogenesis, T lymphopoiesis
continues into adulthood, albeit at a slower rate. Furthermore, and perhaps most pertinent
in the context of these studies, there is a close relationship between development and
oncogenesis. That is, many of the factors that regulate development also drive the
oncogenic process (recent reviews include (91-94)).
The transcriptional repressors GFIl and GFIlB have been identified as oncogenes
and perform defined oncogenic functions. Indeed, these factors were originally identified
in Moloney Murine Leukemia Virus-induced leukemia systems, and were characterized
as being able to block growth arrest, differentiation, and apoptosis (8-10;31 ;62;76).
Sequence analysis of Gfil and Gfil B revealed extensive homology in both the N-terminal
region, which encodes the transcriptional repressor SNAG domain, and in the C-terminal
region encoding six Cis-His Zn fingers (Figure 3) (10). Furthermore, in vitro assays
revealed that GFIl and GFIlB bind to nearly identical recognition sequences and repress
transcription in a SNAG-dependent manner (9;10;15). However, Gfil and GfilB showed

135

tissue-specific expression patterns (10), leaving an apparent dichotomy; if these two
factors are biochemically and functionally redundant, why are there two differentially
expressed proteins?
This work was initiated to address the question of functional redundancy between
GFIl and GFIlB. We chose to examine the effects of transgenic expression ofGFIl or
GFIlB in T cells because GFIl had already been shown to have a biological function in
these cells. During the course of our work, other literature has also emerged examining
the effects of either transgenic expression of GFIl or deficiency of either Gfil or Gfil B.
What has emerged from the work done to date is a story of two unique factors, each
having distinct roles in development. Gfil is essential for normal T lymphopoiesis and
granulopoiesis, while GfilB is required for definitive erythropoiesis (11;16-18). The
published findings of the studies producing these data have been mentioned in more
detail throughout the earlier chapters of this dissertation, and will not be discussed further
here. Instead, this chapter will focus on the distinct roles ofGFIl and GFIlB in positive
selection of developing thymocytes, drawing both from a body of published literature and
from the data generated in this lab and presented in this dissertation.
Based on early biochemical studies, we began this work with the hypothesis that,
if expressed independently in the same tissue and in the same manner, GFIl and GFIlB
may perform redundant functions. To test this hypothesis, mice were generated to
express transgenic GFIl or GFIlB in developing and mature T cells. One of our first
observations of GFIl transgenic T cells is that they respond more robustly to activation
through the TCR (Figure 8), a result that has been corroborated by others (21). On the
contrary, the same analysis applied to GFIlB transgenic T cells yielded a directly
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opposite result. That is, GFIlB-transgenic T cells are defective in activation (Figure 8).
This was perhaps surprising at first, given the biochemical similarities of GFIl and
GFIlB. However, the opposing functions of these two factors in T cells may have been
suggested by very early studies in which GFIlB was found to be up-regulated in
Moloney Murine Leukemia Virus (MoMuLV)-induced B cell tumors, but not in tumors
of T cell origin (10). Since T cells require TCR signals to survive, the lack of GFIl B in
these tumors may have been a clue to the detrimental effect ofGFIlB on TCR-mediated
activation.
Our data suggest that GFI 1B negatively affects normal positive selection of
thymocytes by interrupting TCR signaling events. GFIl is required for normal T
lymphopoiesis (11; 16). Thymi of our GFIl and GFIl B transgenic mice have different
phenotypes. Our GFIl transgenic system failed to reproduce the phenotype observed in
an earlier publication (36), a result that will be discussed in more detail below. However,
our GFIlB transgenics displayed abnormal thymocyte development, manifested by an
increase in the CD4/CD8 ratio and a decrease in the expression of the late activation
marker IL7Ra. Furthermore, in two independent mouse models that express specific
MHC Class II restricted TCRs, the expression of transgenic GFIIB resulted in a decrease
in the number ofCD4 SP cells. This result suggests that overexpression ofGFIlB
interferes with positive selection of DP thymocytes. In addition, our data show that
Gfil B is up-regulated in thymocytes that are undergoing positive selection events.
Considered together with the GFIlliterature and the effects ofGFIl and GFIlB on T cell
activation, our data implicate GFIl and GFIlB in TCR signaling.
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I propose a model ofT lymphopoiesis in which GFIl enhances, while GFIlB
opposes, positive selection. I propose that these opposite effects are engendered by at
least two mechanisms. One mechanism is the distinct activities ofGFIl and GFIlB that
result from their unique intervening sequences. The other mechanism is direct repression
of GjiJ by GFIlB at the DP stage during which TCR signaling must be fine-tuned in
order for proper selection to occur. (See Figure 30.) Furthermore, I propose that these
effects can be observed at earlier stages of thymocyte development, a concept that will be
expanded below.
Evidence for the stimulatory effect of GFIl on positive selection comes from the
study of GFIl transgenic mice. First, as mentioned throughout this dissertation as a
fundamental finding, GFIl transgenic T cells are more responsive to TCR stimulation
than are wild type T cells. TCR signaling is required for positive selection. This
requirement raises the possibility that enhanced signaling may result in enhanced
selection. Conversely, because an overly strong signal results in negative selection, it
remains possible that by enhancing TCR signaling, GFIl could actually increase negative
selection as opposed to positive selection, resulting in an overall decrease in the
production of SP thymocytes. However, in one published report, GFIl transgenic thymi,
though drastically reduced in overall cell number, showed an increase in the percentage
of SP thymocytes and a decrease in the percentage of DP thymocytes when compared to
littermate controls (36). This increase occurred with no consistent bias toward either the
CD4 or CD8 lineage. A simple precursor-progeny ratio, then, would suggest that GFIl
does indeed enhance the positive selection of DP thymocytes.
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Evidence for the deleterious effect ofGFIlB on positive selection has been
presented in chapters 3 and 5 of this dissertation. Our data show that in isolation,
transgenic expression ofGFIlB results in an abnonnally matured population ofCD4 SP
cells and a decrease in the number of CD8 SP cells that are generated. The lack of CD8
SP cells in GFIIB transgenic mice suggested defective positive selection, but was made
less precise in light of the increased numbers ofCD4 SP cells. However, we
hypothesized that the increased number ofCD4 SP cells in the GFIlB transgenics is itself
the result of decreased TCR signals. This aberrant signaling leads to the positive
selection of cells that should have been eliminated. These abnonnal cells are then unable
to develop further into functional immune cells and exit the thymus. Indeed, in the
restricted selecting environment engendered by expression of a Class II-restricted
transgenic TCR, transgenic GFIlB decreases the number ofCD4 SP cells that are
generated, with a concomitant increase in the DP population. Again, precursor-progeny
relationship would suggest a defect in positive selection. Therefore, it seems logical that,
due to a lack of proper TCR and/or IL7 signaling, GFIlB transgenic thymocytes are at a
disadvantage for survival.
The decrease in CD8 SP cells observed in GFIlB single transgenic mice has been
tied both to decreased expression ofIL7Ru and to a lack ofGFIl expression. The partial
restoration of this population by forced expression of GFIl not only emphasizes the
effects of GFIl B-mediated repression of Gfil, but also places GFIl uniquely in the path
of CD8 SP development and further supports a role for GFIl in survival and positive
selection. Furthennore, these data highlight the distinct roles ofGFIl and GFIlB in
thymocyte development. The most straightforward explanation for the results is that
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Figure 30. Schematic representation of GFIl and GFIlB in positive selection of DP
thymocytes. A. The effect of overexpression of GFIl. Too much GFIl results in
increased positive selection and an imbalance of SP to DP cells, in the direction of SP.
The region between the SNAG domain and the Zn fingers is encircled and is likely to
mediate this GFIl-specific effect. B. The effect of overexpression ofGFIlB. Too much
GFIlB results decreased positive selection and an imbalance of SP to DP cells in the
direction ofDP. Both SNAG-dependent complete repression ofGfil and SNAGindependent GFIlB-specific functions contribute to this effect. The unique region of
GFIlB is encircled. C. GFIl and GFIlB in normal positive selection. Moderate
expression ofGFIlB results in moderate repression ofGfil and proper levels ofGFIl
protein. Thus, both factors are present to contribute unique functions and maintain
proper balance of signals, leading to normal positive selection.
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the unique region of GFIl is responsible for supplying the survival signal necessary for
CD8 SP fonnation, which GFIIB is unable to provide. It is interesting to consider that
GFIl has been shown to physically interact with Protein Inhibitor of Activated STAT
(PIAS)3, an inhibitor of Signal Transducer of Activated T cells (STAT)3, through this
unique region. STAT3 has been shown to transduce signals through both IL2 and IL6
pathways in T cells, although a function for STAT3 in T lymphopoiesis has not been
defined. The interaction of GFIl with PIAS3, and possible implications thereof, are
discussed in further detail below. However, though strictly correlative, these data suggest
a role for GFIl-mediated STAT3 activation in the generation and selection of CD8 SP
thymocytes.
The most novel data presented in this dissertation are those that predict a role for
GFIlB in nonnal T lymphopoiesis. In addition to the evidence gleaned from transgenic
mouse models, we and our collaborators have provided the first evidence that GFIlB is
expressed in nonnal developing thymocytes (Figure 6). This physiological expression of
GjilB at stages of positive selection provides insight into the function ofGFIlB in T

cells. Furthennore, our data showing repression of Gjil by GFIlB begins to elucidate a
partial mechanism for the action of GFIIB in T cells; to specifically repress the
transcription of the gene encoding the signal-enhancing factor GFII, thereby providing a
damper of TCR signaling in cells poised to differentiate into the SP stage. However, I do
not suggest that all of the functions of GFIl B are dependent upon its repression of Gjil.
Indeed, we have provided evidence to the contrary in that transgenic GFIl does not
correct all of the phenotypes engendered by transgenic expression ofGFIlB. However, it
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remains possible that the inability of transgenic GFIl to reverse all phenotypes of
transgenic GFIlB is a result of inadequate expression of the transgene.
At least two other possible mechanisms could contribute to GFIlB's function in T
cells. The first is direct competition with GFIl for specific target genes that are
differentially regulated by GFIl and GFIlB. The other is unique GFIlB-specific
interaction with other proteins that have functions in signal transduction. In fact, though
distinct in execution, each of these proposed mechanisms is dictated by the unique nonhomologous central regions ofGFIl and GFIlB.
The first proposed molecular mechanism ofGFIlB antagonism ofGFIl function
in T cells is the direct competition ofGFIl and GFIlB for binding to target genes. For
antagonistic functions to result from one or the other factor binding preferentially to
target genes, the genes in question must be differentially regulated by GFIl and GFIlB.
This differential regulation must be mediated by the non-SNAG or Zn finger regions of
the two proteins. These non-homologous regions may provide different protein-protein
interaction domains that would interact with different transcription factors or co-repressor
(or co-activator) proteins, thereby providing the basis for differential regulation. These
interactions could in fact influence the DNA binding ofGFIl and GFIlB, or the distinct
nature of the interactions may change the context of transcriptional control after DNA
binding. Either mechanism could result in opposing outcomes dependent on the presence
of either GFIl or GFIl B.
Interaction with different binding partners could alter the DNA binding
specificities of GFIl and GFIlB. It can be assumed that these two factors normally exist
in a complex with other proteins, which would bind to DNA as a unit. Our EMSA data
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would suggest that this is true for GFIl (Figure 21). In this proposed mechanism, the
components necessary for interaction are complexed together before being recruited to
DNA. Therefore, ifGFIl and GFIlB are part of pre-existing complexes before binding
to DNA, the presence of the interacting partners could alter the DNA binding of GFIl
and GFIlB in at least two ways. If the interacting partner is itself a transcription factor
with a distinct DNA recognition sequence, it is likely to change the affinity of GFIl or
GFIlB binding by itself making contact with the DNA in the presence of its recognition
element. This interaction would in turn stabilize the overall protein-DNA interaction and
increase the apparent affinity ofGFIl or GFIlB for its binding site. Alternatively, the
GFIl- or GFIlB-interacting proteins present in the pre-formed nuclear complex may not
bind to DNA at all. Rather, they could impose a slight conformational change in GFIl or
GFIlB, thereby slightly altering the affinity for binding. The non-homologous nature of
the intervening sequences ofGFIl and GFIlB suggest distinct protein-protein
interactions and unique binding partners. Therefore, the mechanisms discussed above
would confer differential regulation of target genes in at least two ways. First, binding
affinities ofGFIl and GFIlB for specific sites would be different. Second, the unique
complexes would likely provide distinct regulation of the target genes.
Another model to consider is transcriptional regulation in the context of a
repressosome. Repressosomes and enhanceosomes are nucleoprotein complexes that
assemble on regulatory regions of DNA to regulate the transcription of genes (recently
reviewed in (95-97)). The success of a repressosome depends on the DNA recognition
sequences of specific transcription factors and on the presence of the factors themselves.
Furthermore, proper binding of the DNA-interacting factors specifies the conformation
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for the recruitment of specific co-repressors. When all components are present, the
repressosome is assembled into a three dimensional structure that often involves bending
of DNA to bring transcription factors into close proximity to one another, allowing
necessary protein-protein interactions. Therefore, in this very complex system, the
composition of molecular species is very tightly controlled. That is, incorporation of a
non-functional factor, or perhaps the wrong factor, would result in interruption of the
protein-protein interactions that ensure proper repressosome formation and subsequent
transcriptional regulation by the repressosome complex. The intervening sequences of
GFIl and GFIlB are dissimilar and therefore would not be predicted to interact with
similar proteins. Thus, if GFIl B were to bind to a recognition site that is part of a GFIlrequiring repressosome, then the final transcriptional regulation would not be correct.
This theory, again, depends on the non-homologous regions ofGFIl and GFIlB to confer
the differences. However, this model is more likely to be relevant in situations where one
or the other factor is aberrantly overexpressed, as the binding of the correct factor in the
repressosome would stabilize the tertiary structure. This stabilization would energetically
favor the binding of the correct factor such that this would be the prevalent composition
unless enough of the incorrect factor was present to shift the equilibrium of binding.
The second proposed molecular mechanism is quite straightforward, and therefore
very attractive to consider, though there is very little evidence to support it as yet. GFIl
has been shown to confer signaling advantages to cells by increasing the activity of
Signal Transducer of Activated T cells (STAT)3. GFIl does this by interacting with, and
interrupting the function of, Protein Inhibitor of Activated STAT (PIAS)3 (20). PIAS3
inhibits the DNA binding capability of activated STAT3 by binding to and sequestering
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the active STAT3 dimer (98). However, PIAS3 has also been shown to have other
effects in the cell, including mediation of sumoylation through interaction with SUMO-l
(99; 100). SUMO is a small molecule that resembles ubiquitin and is conjugated to
proteins in a process similar to ubiquitination. However, sumoylation often occurs on
transcription factors in the nucleus, and does not lead to proteasomal degradation.
Rather, sumoylation regulates the subnuclear localization and activity of the target
transcription factors (101). Therefore, GFIl-PIAS3 interaction may signify alterations in
GFIl's transcriptional activity in addition to interference with STAT3 activity.
The interaction of GFIl with PIAS3 has been mapped to the region between the
SNAG domain and the Zn fingers (20), which shares no homology with the same region
ofGFIlB. Therefore, the unique region ofGFIl can act to sequester signaling proteins
and change the context of signaling pathways independent of any direct transcriptional
repression. It is interesting to consider that PIAS3 is likely only one of several proteins
with which GFIl can interact, and that GFIl B, due to having no homology to GFIl in
this region, at the very least does not interact with the same signal-enhancing proteins as
does GFIl and may indeed interact with different proteins to confer opposite effects on
signal transduction.
These same principles may be in place earlier in T lymphopoiesis. GFIl has been
suggested to playa role in early thymocyte development at the stage of beta selection,
which occurs at the DN3 stage of thymocyte development (11 ;36). Our data have shown
that Gfil B is up-regulated at this stage of development. It is therefore possible that,
similar to its effect on TCR signaling, GFIlB decreases pre-TCR-mediated signals to
influence these early maturation steps. However, our GFIl transgenics did not reproduce
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the published phenotype, nor did we observe an effect of transgenic GFIlB at this stage.
Therefore, the roles of GFIl and GFIlB in beta selection cannot be clearly defined at this
point. Nonetheless, there does seem to be a function for GFIl prior to beta selection, as
determined by examination of Gfil deficient mice and corroborated by data from our
GFIlB transgenics.
Mice that are deficient for Gfil display a severe block to T lymphopoiesis in the
very early DNI to DN2 transition (11). Our expression data corroborate a role for GFIl
at this step in that we observe an approximately IO-fold increase in Gfil message levels
in DN2 versus DNI cells (Figure 6). This increase in expression suggests a requirement
for the presence of GFIl in this transition, and supports the result that lack of Gfil causes
a block in early thymocyte development. Furthermore, GFIl transgenic mice have a
larger percentage of both a/~ TCR-expressing and ,,(IS TCR-expressing cells in total
thymocyte populations (36). While the increase in a/~ cells may be attributed to the
previously mentioned increase in the percentage of SP thymocytes, the increased
percentage of ,,(IS T cells should be manifested in the DN population, as ,,(IS lineage
commitment occurs prior to expression of either CD4 or CD8. Furthermore, normal ,,(IS
T cells do not express either co-receptor. We observed a similar result in our GFIlB
transgenic mice. Upon examination ofDN thymocytes, we discovered a reproducible
marked increase in the proportion of cells that express either TCR (data not shown).
Since both overexpression models show similar results, it is interesting to contemplate
that the effect ofGFIl and GFIlB in early T lineage commitment steps is SNAG and Zn
finger dependent. In normal thymocytes, only Gfil is expressed at these very early
stages, further suggesting redundancy of these two factors at this stage. Again, these data
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are merely suggestive, and require more specific experiments to finally answer the
question of the role of GFIl in early T lineage commitment.
GFIl and GFIlB, in addition to being potent oncogenic factors, are important
regulators of development. The normal physiological functions of these two proteins are
just beginning to be understood. The dramatic abnormalities engendered by a complete,
unconditional loss of either factor make gene-targeted mouse systems less than ideal for
studying the subtle nuances of temporal or conditional changes in expression, such that
are likely to be encountered in disease states. Work in the near future is likely to include
conditional knockout systems in which loss ofGjil or GjilB can be directed to specific
cells at specific stages of development. Such experiments in developing T lymphocytes
would clarify some of the finer points of control that these two fascinating transcription
factors mediate during the process of T lymphopoiesis.
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LIST OF ABBREVIATIONS
TCR; T cell receptor
MHC; Major histocompatibility complex
GFIl; Growth factor independence-I
GFIlB; Growth factor independence-IB
IL 7; Interleukin 7
IL 7R; Interleukin 7 receptor
NK; Natural killer
RAG; Recombinase activating gene
DN; Double negative
DP; Double positive
SP; Single positive
EGRI; Early growth response-I
NF AT; Nuclear factor of activated T cells
NFKB; Nuclear factor kappa B
AP-I; Activator protein 1
BCL2; B cell lymphoma 2
MAPK; Mitogen activated protein kinase
IL-2; Interleukin 2
SNAG; Snail and GFIl
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TRAF5; TNFR-associated factor 5
LKLF; Lung Kruppellike factor
ID; Inhibitor of DNA binding
ChIP; Chromatin immunoprecipitation

sacs; Suppressor of cytokine signaling
FACS; Fluorescence activated cell sorting
RT-PCR; Reverse transcriptase-polymerase chain reaction
WT; Wild type
IRF -1; Interferon regulatory factor-1
SEM; Standard error of the mean
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